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Summary
Diphtheria  is  an  infectious  disease  caused  by  toxigenic  Corynebacterium spp.  that  produce
diphtheria  toxin  (DT).  Diphtheria  is  a  significant  health  problem  in  countries  with  poor
immunization coverage or disrupted immunization programs. Even in countries where the disease is
well controlled, there is a need to maintain a stockpile of therapeutic diphtheria antitoxin (DAT) for
management of sporadic or imported cases. Currently, diphtheria is still treated with equine sera in
the same way it was treated more than 100 years ago by Emil von Behring.
Antibodies against DT have been generated from immune and naive human antibody gene libraries
by  phage  display.  The  panning  was  performed  on  unnicked  DT  once  classically  with  DT
immobilized on a microtiterplate and once with biotinylated-DT in panning in solution. Among both
panning strategies, 660 monoclonal antibodies were selected.  The first  screening was either for
binding of the antibodies against diphtheria toxin or for neutralization of diphtheria toxin in a cell-
based  assay.  In  total,  439  antibodies  were  further  characterized  in  scFv-Fc  format  regarding
neutralization in a cell-based  in vitro neutralization assay. In this assay,  290 scFv-Fc antibodies
showed neutralization potency. The best 35 neutralizing scFv-Fc were sub-cloned into IgG1 format. 
Three best neutralizing lead candidates were selected, one against each of the three domains of DT.
The IgG targeting the receptor binding domain is ewe372-D4 and has a neutralization potency of
446 IU/mg. ewe375-H4 has a neutralization potency of 20.4 IU/mg and binds the catalytic domain
and ewe372-F6 binds the translocation domain with a neutralization potency of 2.25 IU/mg. In
comparison, neutralization potency of equine DAT is approximately 50 IU/mg. In this study, seven
antibodies with a higher neutralization potency then equine DAT were developed, and they all bind
the receptor binding domain of diphtheria toxin. In the next step, experiments in a non-lethal guinea
pig model were conducted to test  in vivo protection potency. Possible prospects include further
development and testing of these antibodies for clinical application as therapeutic agents against
diphtheria toxin.
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Zusammenfassung
Diphtherie ist eine Infektionskrankheit, die durch  Corynebacterium spp. verursacht wird, die das
Diphtherie Toxin (DT) produzieren. Diphtherie ist ein großes Gesundheitsproblem in Ländern mit
schlechter  Impfrate  oder  beeinträchtigten  Impfprogrammen.  Selbst  in  Ländern,  in  denen  die
Krankheit  gut  kontrolliert  wird,  ist  es  notwendig,  einen  Vorrat  an  therapeutischem Diphtherie-
Antitoxin  (DAT)  für  die  Behandlung  von  sporadisch  auftretenden  oder  importierten  Fällen  zu
halten.  Diphtherie wird heutzutage immer noch mit Pferdeseren behandelt,  wie es vor mehr als
100 Jahren von Emil von Behring entwickelt wurde.
In  dieser  Arbeit  wurden  Antikörper  gegen  DT  aus  immun-  und  naiven-  menschlichen
Antikörpergenbibliotheken  durch  Phagen  Display  erzeugt.  Das  Panning  wurde  an  nativem DT
einmal klassisch mit immobilisiertem DT in einer Mikrotiterplatte und einmal mit biotinyliertem
DT mit Panning in Lösung durchgeführt. Insgesamt wurden 660 monoklonale Antikörper selektiert.
Das  erste  Screening  erfolgte  entweder  zur  Bindung  der  Antikörper  gegen  DT  oder  zur
Neutralisierung  von  DT  in  einem  zell-basierten  Assay.  Insgesamt  wurden  439  Antikörper  im
scFv-Fc-Format hinsichtlich der Neutralisation in einem zell-basierten  in vitro Neutralisationstest
weiter charakterisiert.  In diesem Assay zeigten 290 scFv-Fc-Antikörper eine Neutralisation.  Die
besten 35 neutralisierenden scFv-Fc wurden in das IgG1-Format kloniert.
Es  wurden  die  drei  best  neutralisierendsten  Kandidaten  ausgewählt,  einer  gegen  jede  der  drei
Domänen  von  DT.  Der  Antikörper  ewe372-D4  bindet  an  die  Rezeptorbindungsdomäne  und
neutralisiert  mit  446 IU/mg.  ewe375-H4  bindet  die  katalytische  Domäne  und  neutralisiert  mit
20,4 IU/mg und ewe372-F6 neutralisiert durch Bindung an die Translokationsdomäne mit 2,25 IU/
mg. Das polyklonale DAT (Pferdeserum) neutralisiert mit ca. 50 IU/mg. In dieser Studie wurden
sieben Antikörper  mit  einer  höheren Neutralisationsrate  als  Pferde-DAT entwickelt,  die  alle  die
Rezeptorbindungsdomäne  des  Diphtherie  Toxins  binden.  Anschließend  folgen  Experimente  in
einem nicht tödlichen Meerschweinchen Modell, um die Protektion in vivo zu testen. Die aus dieser
Studie stammenden Antikörper können für die klinische Anwendung als Therapie gegen Diphtherie
weiterentwickelt werden.
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1 Introduction
1 Introduction
Antibodies are proteins postulated first in the 19th century. The German physiologist Emil
von Behring experimented with blood serum for the treatment of tetanus and diphtheria
(Behring and Kitasato 1890). He found that the serum of immunized animals is protective
against tetanus, respectively diphtheria toxin. His conclusion was, that the serum contains
anti-toxin  substances.  This  serum  therapy  was  a  breakthrough  for  the  treatment  of
diphtheria,  especially  children,  and  was  awarded  1901  with  the  first  Nobel  Prize  in
physiology or medicine.
In 1897, Paul Ehrlich published the first immunological concept, the side chain theory. He
postulated that chemical receptors were produced by blood cells and that these receptors
fitted to entering toxins like a key to a lock (key-lock principle). More than 50 years later,
the antibody structure was discovered (Edelman and Gally 1964; Porter 1959).
Antibodies  are  indispensable  molecules  for  research,  therapy  and  diagnostic.  The  first
therapeutic  antibody  (Orthoclone  Okt3)  was  approved  1986  (Emmons  and  Hunsicker
1987) and generated by hybridoma technology (Köhler and Milstein 1975). This method of
generating antibodies is really time-consuming, expensive and needs the immunization of
animals. An in vitro alternative method for antibody generation is antibody phage display.
Phage display is a powerful tool which offers a rapid, efficient and relatively inexpensive
method for developing antibodies independent of any immune system. The first therapeutic
antibody  developed  by  phage  display  (adalimumab)  was  approved  2003  (Frenzel,
Schirrmann, and Hust 2016). Until now (status autumn 2018), 85 therapeutic antibodies
have been approved as drug, eleven of which were discovered by phage display, and the
number will increase in the next years.
1.1 Antibody
Antibodies are glycoproteins and also known as immunoglobulins (Ig). They are produced
by B cells and are found in the blood plasma and extracellular fluids. Antibodies are Y-
shaped molecules and have a variable region with two arms for binding and one of the five
constant parts that defines the isotype of the antibody. It exists five isotypes of antibodies:
1
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IgA, IgD, IgE, IgG and IgM. Each of these isotypes have a defined role in the immune
system. The predominant isotype in the human serum are IgG antibodies, and they are
responsible for the immunity against invading pathogens (Murphy et al. 2009).
IgG consist of four polypeptide chains, two identical light and heavy chains (figure 1). The
chains are linked by disulfide bridges. The heavy chain of IgG consists of four different
regions with different functions. The variable area (VH) represents the N-terminal part of
the heavy chain followed by a constant domain (CH1). Responsible for the flexibility is the
hinge  area.  The  C-terminal  constant  domains  (CH2  and  CH3)  mediate  activation  of
complements or binding of effector cells via their Fc receptors. The light chain consists of
two domains: the N terminal variable (VL) and the C-terminal constant part (CL1) (Abbas
et al. 2015).
A papain digested IgG antibody results in a Fab-format. When removing the constant part
of a Fab the smallest fragment with an antigen binding site is generated, a single chain
fragment of a variable part (scFv) (figure 1). Here, a peptide linker is needed to stabilize
both  fragments  because  the  cystein  of  the  constant  part  is  missing  that  facilitates  the
formation of a disulfid bond to covalently bind the two constant parts. To obtain a IgG-like
format, a Fc-part can be added to the scFv. This bivalent scFv-Fc antibody format shares
many properties with IgG (Jäger et al. 2013). These antibody fragment formats can all be
generated recombinantly (F. Breitling and Dübel 1997).
2
Figure  1:  Recombinant  antibody
formats compared to IgG.
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1.2 Antibody phage display technology
Antibody  phage  display  is  a  key  technology  to  generate  antibodies,  mainly  human
antibodies,  in  vitro,  independent  of  the  restriction  of  the  immune  system  (Winter  and
Milstein 1991). This technology is based on the work of G.P. Smith (Parmley and Smith
1988). The antibody technology was developed independently on three sites in parallel and
published 1990/91 by John McCafferty in Cambridge (UK) (McCafferty et al. 1990), by
Carlos Barbas III in La Jolla (USA)  (Barbas et al. 1991) and by Breitling and Dübel in
Heidelberg (DE) (Frank Breitling et al. 1991). 
Filamentous phage are used for phage display, because they consist of one circular single
strand DNA surrounded by thousands of coat proteins (pVIII). On one side five copies of
the protein pVII and pIX are located and on the other side five copies of pIII and pVI.
Most  common  for  M13  bacteriophage  based  systems  is  the  coupling  of  an  antibody
fragment to the pIII protein, but also coupling to pVII and pIX are described (Gao et al.
2002; Kwaśnikowski, Kristensen, and Markiewicz 2005). In this pIII system, an antibody-
pIII fusion is formed which leads to a coupling of genotype and phenotype (Frank Breitling
et al. 1991). For phage display, mainly the single chain fragment variable (scFv) (Hust et
al. 2011; Schofield et al. 2007) are used.
When the M13K07 phage is used to package the phagemids, just some particles will carry
an antibody-pIII fusion on the surface. The wildtype pIII of M13K07 competes with the
fusion-protein  pIII  encoded  on  the  phagemid.  To  increase  the  number  of  presented
antibodies on the phage surface, the so-called hyperphage can be used. Hyperphage is a
M13K07ΔpIII phage, where the pIII gene is partial deleted, thus, the phagemid is the only
source for functional pIII (Rondot et al. 2001).
1.2.1 Antibody gene libraries
The human germline contains a lot of different genes for the variable region of the heavy
and  light  chain  (V gene).  The  variable  region  of  the  heavy  chain  (VH)  locus  is  on
chromosome 14, 1,100 kb long and contains 51 functional VH gene fractions as well as the
same number of pseudogenes (Cook and Tomlinson 1995). The variable region of the light
chain (VL) locus is on chromosome 22 and at 800 bp 52 V λ genes are located (Frippiat et
3
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al. 1995). All these different VH and VL fused by a short peptide linker are used to develop
an antibody gene library.
There are different types of antibody gene libraries, universal and immune libraries. Their
usage depends on the scientific or medical application they are constructed for. An immune
library  is  often  constructed  with  the  V genes  isolated  from  the  blood  of  infected  or
immunized  volunteers.  These  libraries  are  often  used  in  medical  research  to  generate
antibodies against a specific target antigen. The isolated V genes are generated with IgG
specific primers and contain hypermutations and are affinity matured.
Universal  library is  a  general  term to summarize naive,  semi-synthetic  and synergistic
libraries. Universal libraries are developed for isolating antibody fragments that binds to
any  type  of  possible  antigen.  The  semi-synthetic  library  is  often  constructed  with
unrearranged V genes from pre B cells (germline cells), where, on the other hand a fully
synthetic libraries have a human framework with randomly integrated CDR cassettes. The
naive  library  contains  the  naive,  complete  gene  repertoire  isolated  with  IgM  specific
oligonucleotide primer. Often non-immunized volunteers are used to build a naive library
(Hust and Dübel 2010).
1.2.2 Panning
The  in  vitro procedure  for  isolation  of  these  antibody  fragments  from antibody  gene
libraries is called panning. During the panning process the antigen can be immobilized to a
solid surface such as plastic surfaces with high protein binding capacity like polystyrene
microtiter wells (MTPs)  (Hust et al. 2002) or magnetic beads  (Moghaddam et al. 2003).
Another strategy is to select antibodies in solution using biotinylated antigens followed by
a pull-down with streptavidin beads (Schütte et al. 2009).
During panning process physical (e.g. temparture), chemical (e.g. pH) and biological (e.g.
competitor) parameters are controlled and chosen specifically to bind the wanted antigen.
For  the selection  in  solution,  the first  step  is  to  incubate  the  antibody phage with the
soluble biotinylated antigen before magnetic streptavidin beads are used for the pull-down.
A stringent washing is performed subsequently to remove the vast excess of non-binding
and weak binding antibody phage. Specifically binding antibodies can be eluted by trypsin
4
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treatment  and  subsequently  used  for  E. coli infection. After  adding  helperphage,  the
antigen specific antibody-phage are amplified. This antibody phage can be used for further
panning  rounds  until  a  significant  enrichment  of  antigen  specific  antibody  phage  is
achieved.  The number  of  antigen  specific  antibody  phage clones  should  increase  with
every panning round.
Normally,  2-3  panning  rounds  are  performed  to  identify  monoclonal  binding  antibody
fragments. For screening of monoclonal binders, they are produced as soluble monoclonal
antibody fragments. These monoclonal antibodies can be identified by e.g. their binding
properties  in  ELISA  (Frenzel  et  al.  2014) or  neutralization  properties  in  cell  based
neutralization assay. Afterwards, the gene fragments encoding the antibody fragments can
be sub-cloned into any other antibody format, e.g. scFv-Fc or IgG (Hust et al. 2011; Hoet
et al. 2005; Frenzel et al. 2014; Jäger et al. 2013). A scheme of the selection procedure is
given in figure 2.
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Figure 2: Schematic workflow for panning in solution (adapted from Viola Fühner, TU Bs)
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1.3 Diphtheria
Diphtheria is an infectious disease and mainly caused by a corynebacteriophage bearing
Corynebacterium  diphtheriae. The  C.  diphtheriae is  gram-stain-positive,  straight  or
slightly curved rod, frequently swollen at one or both ends (club-shaped), 0.3 – 0.8 μm ×
1.0 – 8.0 μm. It is an aerobic bacterium, non spore-forming and non motile. Descriptive
cultural  types  or  biovars  (=  biotypes)  of  C.  diphtheriae strains  are  designated  gravis,
intermedius,  mitis  and  belfanti.  Designations  for  gravis,  intermedius,  and  mitis  were
originally given in accordance with the clinical severity of cases from which the different
strains were most frequently isolated (Bernard and Funke 2015). The bacterium primarily
infects  the  throat  and  upper  airways.  The  produced  toxin  can  spread  through  the
bloodstream and affects other organs, such as heart and kidneys. Diphtheria has an acute
onset and the main symptoms are sore throat, low fever and swollen glands in the neck. In
severe cases, diphtheria toxin may cause myocarditis or peripheral neuropathy. Due to a
membrane of dead tissue over the throat  and tonsils,  swallowing and breathing can be
difficult. The disease is spread through direct physical contact or by coughing or sneezing
of infected individuals (“WHO | Diphtheria” 2018).
Diphtheria toxin can also be produced by  C. ulcerans and  C. pseudotuberculosis. These
two stains are less common globally and mostly associated with farm animal contact and
dairy products (Sangal et al. 2014; Peel et al. 1997; Mills, Mitchell, and Lim 1997).
1.3.1 Diphtheria toxin
Diphtheria toxin (DT) was the first investigated bacterial protein toxin and has since been
the most extensively studied one. Thus, it has served as a model system for the analysis of
other protein toxins (Pappenheimer Jr 1977). Corynebacterium diphtheriae was identified
as the causative agent of diphtheria in 1884 and in 1888 the toxin was first described in the
culture medium of C. diphtheriae (Roux and Yersin in 1888). The gene for DT is encoded
on  a  corynebacteriophage  (Greenfield  et  al.  1983;  Uchida,  Gill,  and  Pappenheimer  Jr
1971), and is expressed only under conditions of iron deprivation (Pappenheimer Jr 1977).
DT is secreted as a single polypeptide chain of 535 amino acid residues with a molecular
weight  of  58  kDa  (Smith  et  al.  1980;  Kaczorek  et  al.  1983).  Mild  trypsinization  and
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reduction  of  DT  in  vitro generates  two fragments,  A and B,  which  remain  covalently
attached  by  an  inter-chain  disulfide  bond  (Gill  and  Pappenheimer  1971).  Fragment  A
contains the enzymatic activity (Collier and Kandel 1971), whereas Fragment B binds the
protein to the cell surface receptors and promotes transfer of fragment A to the cytoplasm
(Drazin,  Kandel,  and  Collier  1971).  DT is  composed  of  three  structural  domains:  the
catalytic domain (C) corresponds to fragment A (21 kDa), the transmembrane (T) domain
(20 kDa) and receptor binding (R) domain (17 kDa) are included in fragment B (37 kDa)
(Figure 3) (Choe et al. 1992).
Diphtheria  toxin  binds  with the  receptor  binding domain  to  heparin-binding  epidermal
growth factor  (HP-EGF) on the  cell  surface of  susceptible  cells.  This  binding triggers
receptor-mediated  endocytosis  of  the  toxin  (Dorland,  Middlebrook,  and  Leppla  1979;
Morris and Gerstein 1985). Acidic conditions in the endosome leads to a confirmational
change  and  permits  the  translocation  domain  of  DT  to  form  a  channel  through  the
endosomal  membrane.  Through this  channel  the  C-domain  is  released  into the  cytosol
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Figure  3:  Protein  structure  of  diphtheria
toxin with the 3 domains: C-domain (red), T-
domain  (blue)  and  R-domain  (green).  A)
crystal structure B) schematic structure.
A
B
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(Draper 1980; Sandvig 1980; Hu and Holmes 1984; Montecucco et al. 1986; Moskaug,
Sandvig,  and  Olsnes  1988;  Kagan,  Finkelstein,  and  Colombini  1981). After  being
delivered into the cytosol, the C-domain catalyzes the NAD+-dependent ADP-ribosylation
of  elongation  factor  2  (EF-2).  EF-2  is  the  only  known substrate  for  the  C-domain  in
eukaryotic cells and it is involved in protein synthesis (Pappenheimer Jr 1977).
A post-translational modification of a histidine residue in EF-2 (diphthamide) is the known
site  of  action  of DT.  Here,  transfer  of  an ADP-ribosyl moiety  of  NAD+ results  in  the
irreversible arrest of chain elongation during protein synthesis  (Collier  and Cole 1969).
This arrest leads to cell death by apoptosis. (Ratts and Murphy 2012).
DT, especially diphtheria toxoid (DTd), was well studied and characterized and due to its
mode  of  action  and  immunogenicity.  It  is  a  good  agent  for  vaccination.  But  the
detoxification with formaldehyde creates heterogeneous molecules that leads to a purity of
diphtheria toxoid of 60 – 70 %. Moreover, DTd can lose its natural structure and epitopes
due to formaldehyde treatment (Metz et al. 2003).
An alternative to DTd was Cross Reactive Material  197 (CRM197). Here, the catalytic
center of DT was genetic modified by a point mutation (G52E) to a non-toxic DT mutant
with same confirmation (Uchida, Pappenheimer, and Harper 1973). Later, it was observed
that the conformation of DT and CRM197 is not identical but similar  (Bigio et al. 1987;
Malito et al. 2012). This CRM197 is nowadays used as vehicle for therapeutic transport in
cells or for children as alternative to DTd for vaccination (Shinefield 2010).
1.3.2 Current therapy
In 1890, it was first demonstrated by von Behring and Kitasato that susceptible animals
could be immunized with C. diphtheriae and the serum of these immunized animals could
protect other animals for diphtheria toxin (DT). In 1891, the first child was cured through
preparation of a serum from an immunized animal. In 1901, von Behring received the first
Nobel Prize in Physiology or Medicine for his development of serum therapy.
In 1923, it was discovered, that DT could be inactivated with formalin without destroying
its immunogenicity. This DTd has since been used as vaccine against diphtheria toxin. The
vaccine  is  normally  given  in  combination  with  other  vaccines  (e.g.  tetanus  and/or
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pertussis). This vaccination against diphtheria has reduced the mortality and morbidity of
diphtheria dramatically, however diphtheria is still a significant health problem in children
in countries with poor immunization coverage. Diphtheria is fatal in 5 – 10 % of cases, but
children  under  the  age  of  five  have  a  higher  mortality  rate  of  up  to  20 %. Treatment
involves antibiotic treatment to kill the bacteria (erythromycin or penicillin for 14 days)
and  administering  of  diphtheria  antitoxin  (DAT) to  neutralize  the  effects  of  the  toxin
(“Diphtheria | Clinical Features | CDC” 2016). This treatment with DAT, a purified serum
from DT-immunized horses, has been the same treatment for more than 100 years now. As
DAT is of animal  origin,  every product batch needs to be tested and screened for the
presence of infectious  agents.  Also,  DAT can cause serum sickness in humans.  Serum
sickness is a type of hypersensitivity  reaction,  due to proteins derived from the equine
serum. The human immune system develops antibodies against foreign antigens from the
animal anti-sera which leads to the formation of immune complexes which can precipitate
in  joints  or  small  vessels,  activating  the  complement  cascade  and  initiating  an
inflammatory response (Kniker 1968; Jackson 2000). Today, DAT is in scarce supply and
frequently unavailable to patients because of discontinued production in several countries
(Both et al. 2014). There is an urgent need of an alternative to the equine DAT. Therefore,
a new treatment with fully human, monoclonal antibodies is desirable.
1.4 Aim of the work
For therapy of diphtheria an equine serum is still used, like Emil von Behring developed it
over 100 years ago. The aim of this work is the generation of recombinant, human anti-
diphtheria toxin neutralizing antibodies to replace the equine serum.
The antibody generation will be done with  in vitro phage display technology. With this
technology  fully  human  antibodies  can  be  selected  without  the  need  for  animal
immunization. The  developed  antibodies  will  be  characterized  regarding  their  binding
ability to diphtheria toxin and their neutralization potency. This characterization will be
shown in the antibody formats scFv-Fc and IgG. Further, the domains will be mapped to
demonstrate against which domain of DT the neutralizing antibodies are binding.
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2 Materials and Methods
2.1 Material
2.1.1 Technical equipment and accessories
The equipment used in this study is listed in the following table 1.
Table 1: List of equipment and accessories
Equipment Name Supplier
Blot device Trans-Blot Turbo Transfer Bio-Rad (München, DE)
ELISA washer Columbus Pro
Columbus Plus
Hydrospeed
Tecan (Crailsheim, DE)
Tecan (Crailsheim, DE)
Tecan (Crailsheim, DE)
ELISA reader SUNRISE 
Epoch
Tecan (Crailsheim, DE)
BioTek (Bad Friedrichshall, DE)
Electroporation device Micro Pulser TM BioRad (München, DE) 
Gel documentation Gel Jet Imager 
Chemi Doc MP Imaging 
System
Intas (Göttingen, DE)
Bio-Rad (München, DE)
Gel electrophoresis 
chamber
PerfectBlue Mini S
PerfectBlue Mini ExM
Mini-Protean 3 Cell 
Peqlab (Erlangen, DE)
Peqlab (Erlangen, DE)
Bio-Rad (München, DE)
Thermomixer Thermomixer comfort 
Thermomixer compact 
Mixing Block MB-102
Eppendorf (Hamburg, DE)
Eppendorf (Hamburg, DE)
Bioer (Binjiang, CHN)
Incubator HeraCell (with CO2)
Incubation-shaker Minitron 
(with CO2) 
Incubation-shaker Multitron
Certomat BS-1
Incubator BE400
VorTemp 56 
Kendro (Langenselbold, DE)
Lab Products Infors HT (Einsbach, 
DE)
Infors HT (Einsbach, DE)
Satorius (Göttingen, DE)
Memmert (Schwabach, DE)
Labnet (Austin, USA)
Power supply EPS 301/601 Amersham Pharmacia (Freiburg, DE)
Thermocycler PTC-200 MJ Research (Waltham, USA)
pH meter CG810 Schott (Mainz, DE)
Spectrophotometer Nano Drop ND1.000 
Libra S11 
Peqlab (Erlangen, DE)
Biochrom (Holliston, USA)
Pipets Research
Pipetman
Proline Plus
Eppendorf (Hamburg, DE)
Gilson (Middelton, USA)
BioHit (Satorius, Göttingen, DE)
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Equipment Name Supplier
Sonicator Bioruptor® Pico Diagenode (Denville, USA)
Pipet helper Acu-Jet Brand (Wertheim, DE)
Protein purification Profinia Bio-Rad (München, DE)
Water purification system Arium 611 Sartorius (Göttingen, DE)
Rocker Titramax 101
Platform Rocker STR6
Heidolph Instruments (Schwabach, 
DE)
Stuart Scientific (Staffordshire, UK)
Laminar flow bench HeraSafe
LaminAir HLB 2472 MSC 
Advantage 
Heraeus Instruments (Hanau, DE)
Thermo Scientific (Waltham, USA)
Vacuum pump Laboport KNF Neuberger (Freiburg, DE)
Vortex Vortex-Genie 1 Scientific Industries (New York, 
USA)
Scale E 1200 S
EMB 220-1 
Analytic A 120 S 
Sartorius (Göttingen, DE)
Kern (Balingen, DE)
Sartorius (Göttingen, DE)
Centrifuge Eppendorf 5810R 
Eppendorf 5415D 
Biofuge fresco 
Multifuge 3 S-R
Eppendorf (Hamburg, DE)
Eppendorf (Hamburg, DE)
Heraeus (Hanau, DE)
Heraeus (Hanau, DE)
Waterbath Waterbath GFL Laborbedarf (Braunschweig, DE)
2.1.2 Consumables
The consumables used in this study are listed in the following table 2.
Table 2: List of consumables used in this study
Consumables Supplier
Air-o-Seal hydrophobic Gas permeable seal 4titude (Dorking, UK)
Blotting paper (550 g/m2) Sartorius (Göttingen, DE)
Chromatography paper 3 mm Whatman (GE Healthcare, Freiburg, DE)
Disposable spatula (L-shape) VWR (Darmstadt, DE)
DynabeadsTM M-280 Streptavidin Thermo Fisher Scientific (Waltham, USA)
Filter sterile 0.45 μm
Filter sterile 0.2 μm 
Sartorius Stedim Biotech (Göttingen, DE)
Whatman (GE Healthcare, Freiburg, DE)
Inoculation loops Sarstedt (Nürmbrecht, DE)
PP Screw lid micro caps 2 mL Sarstedt (Nürmbrecht, DE)
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Consumables Supplier
Microtiter-polypropylene plate 96 well, U-
shape
Greiner Bio-One (Frickenhausen, DE)
Parafilm American National Can (Chicago, USA)
Multiply-μStrip Pro 8-strip Sarstedt (Nürmbrecht, DE)
Petri dish 10 cm
Petri dish 15 cm
Greiner Bio-One (Frickenhausen, DE)
Sarstedt (Nürmbrecht, DE)
Pipet tips 10 μL; 200 μL; 1000 μL; 5000 μL Sarstedt (Nürmbrecht, DE) 
Biohit (Satorius, Göttingen, DE)
Pipet tips, filtered 10 μL; 200 μL; 1000 μL Sarstedt (Nürmbrecht, DE), 
NerbePlus (Winsen, DE)
Polycarbonat Erlenmeyer Flask graduated Corning (New York, USA)
Polypropylen 96 well plate U-shape (Costar) Corning (New York, USA)
Polypropylene tubes (15 mL, 50 mL) Corning (New York, USA)
Polypropylene plate 24 well Sarstedt (Nürmbrecht)
Polystyrene lid Greiner Bio-One (Frickenhausen, DE)
Polystyrene assay plate 96 Well high binding 
(Costar)
Corning (New York, USA)
Dialysis tube MWCO 14000 Carl Roth (Karlsruhe, DE)
PVDF membrane Bio-Rad (München, DE)
Reaction tube 1.5 mL; 2 mL Sarstedt (Nürmbrecht, DE)
Column for Affinity chromatography (Protein 
A), BioScale Mini UNOsphere SUPrA 1 mL
Bio-Rad (München, DE)
Column for Desalting, BioScale Mini Bio-Gel 
P-6 Desalting Cartridge 10 mL
Bio-Rad (München, DE)
Serological pipets 2 mL; 5 mL; 10 mL; 25 mL 
steril
Corning (New York, USA)
Syringe Inject 1 mL; 2 mL; 5 mL; 20 mL B. Braun (Melsungen, DE)
Polystyrene TC plate 12 well/24 well SPL Life Sciences (Pocheon, KOR)
TC plate 96 well V shape with lid Greiner Bio-One (Frickenhausen, DE)
Disposable cuvettes 1.5 mL half-micro Brand (Wertheim, DE)
Cellulose acetate filter 0.45 μm Sartorius Stedim Biotech (Göttingen, DE)
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2.1.3 Chemicals
All chemicals used in this study were purchased from Carl Roth (Karlsruhe, DE), Sigma-
Aldrich  (Taufkirchen,  DE),  Merck  KGaA (Darmstadt,  DE),  AppliChem  GmbH
(Darmstadt, DE), Roche Diagnostics GmbH (Penzberg, DE) and SERVA Electrophoresis
GmbH (Heidelberg, DE).
2.1.4 Solutions and buffers
All  buffers and solutions used in this  study were prepared with ultra  pure water or as
indicated (table 3).
Table 3: List of used solutions and buffers
Buffer/ Solution Recipe
General
Glycerine 80 % (v/v) Glycerine
PBS 137 mM NaCl; 1.76 mM KH2PO4 • 2 H2O
PBS-T 0.05 % (v/v) Tween20 in PBS
DNA electrophoresis 
Agarose gel 1 % (w/v) Agarose in TAE 
Ethidium bromide solution 10 μg/L Ethidium bromide
TAE 40 mM Tris; 20 mM Acetate; 2 mM EDTA 
Coomassie staining
Coomassie®- Destaining 10 % (v/v) Acetic acid
Coomassie®- Staining 10 % (v/v) Acetic acid; 0.05 % (w/v) Coomassie® Brilliant Blue 
R250 
ELISA 
ELISA stop solution 0.5 M H2SO4 
PBST ELISA-Washer 0.05 % (v/v) Tween20 in PBS 
M-PBST (Blocking) 2 % (w/v) Milk powder in PBS; 0.05 % Tween20 
TMB solution A 30 mM Potassium citrate; 1 % (w/v) Citric acid (pH 4.1) 
TMB solution B 10 mM Tetramethylbenzidine; 10 % (v/v) Acetone; 90 % (v/v) 
Ethanol; 80 mM H2O2 (30 %)
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Buffer/ Solution Recipe
TMB solution 20 parts TMB-A; 1 part TMB-B 
Chemical competent cells 
TFB1 10 mM CaCl2; 30 mM Potassium acetate; 100 mM RbCl; 50 mM
MnCl2; 15 % (v/v) Glycerine (pH 5.8)
TFB2 10 mM MOPS; 10 mM Cl; 75 mM CaCl2; 15 % (v/v) Glycerine 
(pH 5.8)
SDS-polyacrylamid gel electrophoresis 
APS-solution 10 % (w/v) Ammonium persulfate in H2O
Laemmli buffer (5x) 500 g/L Glycerine; 100 g/L SDS; 250 mL β-Mercaptoethanol; 
200 mL 1.5 M Tris-HCl (pH 6.8); 0.5 g/L Bromphenol Blue
Running gel buffer 1.5 M Tris-HCl (pH 8.8)
SDS solution 10 % (w/v) SDS
SDS-PAGE buffer 25 mM Tris; 192 mM Glycine; 0.1 % (w/v) SDS solution
Stacking gel buffer 1.0 M Tris-HCl (pH 6.8)
Silver staining
Develop solution 3 g NaCO3; 25 µL 37 % Formaldehyde; 1 mL Sodium thiosulfate
to 50 mL dH20
Fixation solution 50 mL Stop solution; 25 µL 37 % Formaldehyde
Sodium thiosulfate 10 mg Na2S2O3 • 5 H2O to 50 mL dH20
Silver solution 0.5 mL 20 % AgNO3; 37.5 µL 37 % Formaldehyde to 50 mL 
dH20
Stop solution 50 % Methanol; 12 % Acetic acid
Western blot and immuno staining
AP substrate buffer 100 mM Tris; 0.5 mM MgCl2 (pH 9.5)
BCIP solution 1.5 % (w/v) BCIP in 100 % (v/v) Dimethylformamide
Blotting buffer 25 mM Tris; 192 mM Glycine (pH 8.3)
MPBS (Blocking) 2 % (w/v) milk powder in PBS-T
NBT solution 3 % (w/v) NBT in 70 % (v/v) Dimethylformamide
FACS
FACS buffer 1x PBS; 1 mM EDTA
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Buffer/ Solution Recipe
Toxin Neutralisation Test
MTT solution 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) in PBS
MTT Extraction solutiom 50 % DMF; 10 % SDS (pH 4.7)
2.1.5 Materials for cultivation and supplements
2.1.5.1 Prokaryotes
All  media  and  solutions  are  prepared  with  ultra  pure  water  and  autoclaved  or  sterile
filtrated before use for culture of  E. coli (table  4). Supplements are added immediately
prior to use.
Table 4: List of culture media and supplements (prokaryotes)
Medium Recipe
Media
SOC 2 % (w/v) Tryptone; 0.5 % (w/v) Yeast extract; 0.05 % (w/v) NaCl 
(pH 7.0); 20 mM Mg2+ solution (1 M MgCl2, 1 M MgSO4); 20 mM 
Glucose
LB 1 % (w/v) Tryptone; 0.5 % (w/v) Yeast extract; 1 % (w/v) NaCl
2xYT 1.6 % (w/v) Tryptone; 1 % (w/v) Yeast extract; 0.5 % (w/v) NaCl 
(pH 7.0)
2xYT-GA 2xYT medium; 100 mM D-Glucose; 100 μg/mL ampicillin
2xYT-GA-Agar 2xYT medium; 1.5 % (w/v) Agar; 100 mM D-Glucose; 
100 μg/mL ampicillin
2x YT-T 2xYT medium; 20 µg/mL tetracycline
2x YT-AK 2xYT medium; 100 µg/mL ampicillin; 50 µg/mL kanamycin
Supplements
Ampicillin solution 100 mg/mL Ampicillin stock solution
Glucose solution 2 M Glucose stock solution
IPTG solution 1 M Isopropyl-β-D-thiogalactopyranosid stock solution
Kanamycin solution 50 mg/mL Kanamycin stock solution
Tetracycline solution 10 mg/mL Tetracycline stock solution
TN1 Trypton N1 (Casein Pepton)
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2.1.5.2 Eukaryotes
All media, solutions and supplements used for cultivation of mammalian cells are listed in
table 5.
Table 5: List of culture media and supplements (eukaryotes)
Product Supplier Catalog number
Media
MEM Earle’s medium Biochrom F0325
Free StyleTM F17 
Expression medium
gibco® (Life Technologies, 
Darmstadt)
A13835-01
HK-TF Xell AG 861-0001
HK-FS Xell AG 871-0001
Supplements
Trypsin/EDTA Biochrom L2153
Glucose Carl Roth 9155.1
Penicillin/streptomycin Biochrom A2212
L-Glutamine Biochrom K0283
Fetal bovine serum (FBS) Biochrom S0615
DMSO Carl Roth A994.2
HEPES Carl Roth 6763
Pluronic-F68 PANTM BIOTECH P08-02100
2.1.6 Bacterial strains, bacteriophage and cell lines
The bacterial strains and cell lines used in this study are listed in table 6.
Table 6: List of bacterial strains and cell lines
Strain/Cell lines Genotype References
Bacterial strain
E. coli XL1-Blue MRF` _(mcrA)183 _(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1
gyrA96 relA1 lac [F_ proAB 
lacIqZ_M15 Tn10 (Tetr)] 
Stratagene (LA Jolla, USA)
E. coli TG1 K-12 supE thi-1 _(lac-proAB) 
_(mcrB-hsdSM)5, (rK-mK-) F' 
[traD36 proAB+ lacIq lacZ_M15] 
GE Healthcare (Freiburg, DE)
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Strain/Cell lines Genotype References
BLR(DE3) F- ompT hsdSB(rB
- mB
-) gal lac ile 
dcm Δ(srl-recA)306::Tn10 (tetR)
(DE3) 
Merck (Darmstadt, DE)
E. coli ER2738 [F'proA+B+ lacIq Δ(lacZ)M15 
zzf::Tn10 (tetr)] fhuA2 glnVΔ(lac-
proAB) thi-1Δ(hsdS-mcrB)5 
Lucigen (Middleton, USA)
Bacterio phage
Helperphage M13K07 (Vieira and Messing 1987)
Helperphage Hyperphage (Rondot et al. 2001)
Eukaryotic cell lines 
Expi293F™ Cells Derived from HEK293-6E cells, 
optimized for growth in higher 
densities
Thermo Fisher Scientific Inc. 
(Waltham, USA)
Vero (WHO) Provided by NIBSC (Osada et al. 2014)
2.1.7 Expression vectors
The plasmids used in this study are listed in table 7.
Table 7: List of plasmids
Plasmid Description Source
pCSE2.6-hIgG1-
Fc-Xp
Secretion vector for the expression of scFv-Fc-fusions in 
EXPI293F cells 
(Beer et al. 2018; 
Russo et al. 2018)
AG Dübel
pCSE2.7-hIgG1-
Fc-Xp
Secretion vector for the expression of scFv-Fc-fusions in 
EXPI293F cells 
AG Dübel
pHAL30 Phagemid, Phage-Display, Expression of scFvs in E. coli (Kügler et al. 2015)
AG Dübel
pHAL51 Phagemid, Phage-Display, Expression of scFvs in E. coli AG Dübel
pHAL52 Phagemid, Phage-Display, Expression of scFvs in E. coli AG Dübel
pET21a(+) Secretion vector for expression of proteins in BLR(DE3) 
cells
AG Dübel
pCSE1c Secretion vector for the expression of IgG heavy chain in 
EXPI293F cells 
AG Dübel
pCSL3l Secretion vector for the expression of IgG lambda light 
chain in EXPI293F cells 
AG Dübel
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Plasmid Description Source
pCSL3k Secretion vector for the expression of IgG kappa light 
chain in EXPI293F cells 
AG Dübel
2.1.8 Enzymes
All enzymes used in this study are listed in table 8.
Table 8: List of enzymes
Enzymes Supplier
Restriction endonuclease
BstNI, HindIII-HF, NcoI-HF, NheI-HF, NotI-HF,
MfeI-HF, MluI-HF, BsiWI-HF, AgeI-HF, DraIII,
BssHII-HF, AscI-HF
New England Biolabs (Frankfurt a. M., DE)
T4 DNA Ligase New England Biolabs (Frankfurt a. M., DE)
GoTag® DNA polymerase Promega (Mannheim, DE) 
Q5 DNA polymerase New England Biolabs (Frankfurt a. M., DE) 
Phusion DNA polymerase Promega (Mannheim, DE) 
Calf Intestinal alkaline phosphatase New England Biolabs (Frankfurt a. M., DE) 
Trypsin Sigma-Aldrich (Taufkirchen, DE)
2.1.9 Antigens and antibodies
The antibodies and antigens used in this study are listed in table 9 and 10.
Table 9: List of antigens
Antigen Description/ Supplier
A-fragment (= C-domain) Produced in BLR(DE3) with His-Tag
B-fragment Produced in BLR(DE3) with His-Tag
T-domain Produced in BLR(DE3) with His-Tag
R-domain Produced in BLR(DE3) with His-Tag
Diphtheria Toxin (#150) List Biological Laboratories (Campbell, USA)
CRM197 (#149) List Biological Laboratories (Campbell, USA)
Diphtheria Antitoxin Human IgG
(product no 10/262)
NIBSC (London, UK)
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Table 10: List of antibodies
Antibody Catalog No Supplier/ Origin
Mouse α c-Myc Clone 9E10, AG Dübel
goat α mouse IgG HRP (Fc) A0168 Sigma-Aldrich (Hamburg, DE)
goat α mouse IgG AP (Fc γ) 115-055-071 Dianova (Hamburg, DE)
goat α hIgG AP (Fc γ) 109-055-098 Dianova (Hamburg, DE)
goat α hIgG HRP (Fc γ) A0170 Sigma-Aldrich (Hamburg, DE)
mouse α pIII PSKAN3 MoBiTec (Göttingen, DE)
mouse α CD138 (FITC) ab27390 abcam (Cambridge, UK)
mouse α CD19 (PE) ab93562 abcam (Cambridge, UK)
goat α human IgG Fc (APC) 109-135-098 Dianova (Hamburg, DE)
goat α-M13 (pVIII) BM5516F Acris (Herford, DE)
scFv-Fragment (AG Dübel)
DM321-F11 α Lysozym, AG Dübel
2.1.10 Commercial kits
The used kits are listed in table 11.
Table 11: List of commercial kit systems
Kit Description Hersteller 
NucleoBond®PC500 Xtra Midi Preparation of plasmid DNA Macherey-Nagel (Düren, DE) 
NucleoSpin® Plasmid easy pure Preparation of plasmid DNA Macherey-Nagel (Düren, DE) 
NucleoSpin® Gel and PCR 
clean-up
Clean up of DNA-fragments Macherey-Nagel (Düren, DE) 
2.1.11 Software and databases
All software and databases used are listed in table 12.
Table 12: Software and databases
Software Reference Purpose
MultAlgin (Corpet 1988) Sequence alignment
VBase2 (Retter 2004) Analysis of antibody sequences
NCBI http://www.ncbi.uhm.nih.gov Literature, Protein- and Gene-
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Software Reference Purpose
sequences 
LibreOffice https://de.libreoffice.org Text- and data processing
Geneious https://www.geneious.com Generation and analysis of vector 
maps 
GraphPad Prism 6 http://www.graphpad.com/
scientific-software/prism/
Graphical data 
2.1.12 DNA- and protein standards
For  size  determination  of  DNA  agarose  gels,  GeneRulerTM 1kb  Plus  DNA  Ladder
(Fermentas, St. Leon-Rot, DE) was used.  For size determination of proteins in a SDS-
PAGE  followed  by  Coomassie  or  silver  staining,  Precision  Plus  ProteinTM Standards
unstained (Bio-Rad,  München,  DE) was used.  For  Western blot  analysis  with  immuno
staining,  Precision  Plus  ProteinTM All  Blue  Prestained  Protein  Standards  (Bio-Rad,
München, DE) was used.
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2.2 Microbiological methods
2.2.1 Sterilization
Most of the used media and solutions were sterilized by pressurized steam for 20 minutes
at 121 °C. Heat or pressure sensitive substances were sterile filtrated with a 0.2 µm or
0.45 µm filter.
2.2.2 Cultivation of E. coli and cell density measurement
E. coli was cultivated in 2x YT medium supplemented with 0.1 M glucose at 37 °C and
250  rpm.  Depending  on  the  cultivation  aim,  different  substances  and  antibiotics  were
added.  For  single  clones,  E. coli was  plated  on a  2x YT agar  and incubated  at  37 °C
overnight and afterwards inoculated in liquid culture. Density of cells were determined by
measuring the optical density at 600 nm.
2.2.3 Storage
E. coli cells  on  2x YT-Agar  plates  were  stored  up  to  2  weeks  at  4 °C.  For  long-term
storage of bacteria, glycerol cultures were used. Therefor, E. coli was cultured overnight in
2x YT-GA medium. On the next day, freshly cultured E. coli cells were mixed with 80 %
(w/v) glycerol  to final concentration of 20 % (w/v) glycerol. Suspensions were stored at
-80 °C.
2.2.4 Transformation of E. coli by heatshock
Chemically competent E. coli cells were transformed by heat shock. DNA was mixed with
25 µL of E. coli cells and was placed on ice for 20 min. After heating the cells for 60 sec to
42 °C, the cells were cooled down on ice for 2 min. To regenerate the transformed cells,
they were incubated in 250 µL of SOC medium at 37 °C with shaking for 30 min. The cells
were  plated  on a  2x YT agar  plate  with  appropriate  antibiotics.  Plates  were  incubated
overnight at 37 °C.
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2.2.5 Transformation of E. coli by electroporation
Electroporation  was  used  for  the  transformation  of  electro-competent  E. coli cells  for
antibody phage display library construction. Before transforming cells, a buffer exchange
of the DNA was performed 3 times with 470 µL H2O using Amicon Ultra Centrifugal
Filters (30K) (Merck Millipore). Frozen electro-competent E. coli cells were thawed on ice
and  mixed  with  DNA.  The  cell/DNA mixture  was  transferred  to  pre-chilled  (-20 °C)
electroporation cuvettes and transformation was performed at 1.7 kV (E.coli XL1 Blue
MRF’)  or  1.8  kV  (E.  coli ER2738)  (MicroPulser™,  BioRad).  Immediately  after  the
electroporation  pulse,  1  mL of  37 °C  pre-warmed  SOC  was  added.  After  60  min  of
incubation at 600 rpm and 37 °C, cells were plated on 2x YT agar containing appropriate
supplements.
2.2.6 Production of soluble scFvs in microtiter plates
Soluble antibody fragments (scFvs) were produced in microtiter plates. Briefly, 140 µL
2x YT-GA  medium  were  inoculated  with  10  µL  overnight  culture.  Incubation  was
performed at 37 °C and 850 rpm using a microtiter plate shaker. When OD600nm reached a
value of 0.5, the microtiter plate was centrifuged (10 min at 3220 xg) and the supernatant
was  discarded.  To  induce  the  expression  of  the  antibody  genes,  the  pellets  were
resuspended in 150 µL 2x YT-A with 50 µM IPTG and were incubated for 20 h at 30 °C
and  850  rpm.  Cells  were  separated  from  the  antibody  containing  supernatant  by
centrifugation for 10 min at 3220 xg. 
2.2.7 Production and infection of antibody phage
Antibody phage were produced in microtiter plates. Briefly, 140 µL 2x YT-GA medium
were inoculated with 10 µL overnight culture.  Incubation was performed at  37 °C and
850 rpm using a microtiter plate shaker. After incubation of 2 h, the culture were infected
with 5 • 1011 hyperphage particles by incubation at 37 °C for 30 min followed by a second
incubation for 30 min at 37 °C and 850 rpm. The microtiter plate was centrifuged (10 min
at 3220 xg), the supernatant was discarded, the pellets were resuspended in 150 µL 2x YT-
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AK and the plate was incubated for 20 h at 30 °C and 850 rpm. Cells were separated from
the antibody containing supernatant by centrifugation for 10 min at 3220 xg. 
2.2.8 Determination of phage titer
Phage  titers  were  determined  for  preparation  of  antibody  phage  libraries  to  monitor
panning output. Phage titers were determined by infection of  E. coli cells. In PBS a ten-
fold serial dilutions of the phage were prepared. For infection, 50 µL of an  E. coli XL1
Blue MRF’ culture at exponential growth (OD600 = 0.5 in 2xYT-T) was briefly mixed with
10 µL of a phage dilution and incubated at 37 °C for 30 min. After the infection, 3x 10 µL
of  each  dilution  were  spotted  on  2x  YT-GA agar  plates.  The  plates  were  incubated
overnight at 37 °C and on the next day, colonies were counted and the cfu/mL determined.
To exclude phage contamination of the used PBS, a control with 50 µL E. coli culture and
PBS was treated equally to the infection with phage. The used PBS and  E. coli culture
alone was spotted on 2x YT-GA agar plates to exclude bacterial contamination of the PBS
or ampicillin resistance of the  E. coli culture. Another 50 µL of the  E. coli culture were
infected with 10 µL of a phage solution with known titer as a positive control e.g. the
library HAL7.
2.2.9 Selection of antibodies with antibody phage-display
Panning allows the selection of displayed antibodies based on specific binding to a protein.
2.2.9.1 Panning in microtiter plate
For the panning procedure the antigen was immobilized on a 96 well plate. Therefor, 1 µg
diphtheria toxin was diluted in PBS and coated to a well at 4 °C overnight. Afterwards, the
well was blocked with 350 µL blocking solution for 1 h at RT and then washed 3 times
with PBST. Before adding the libraries in the coated well, the libraries (5 • 1010 cfu) were
preincubated with blocking solution on a blocked well for 1 h at RT. The libraries were
transferred to the coated wells, incubated for 2 h at RT and washed 10 times. Bound phage
were eluted with trypsin (10 µg/mL) at 37 °C and 5 µL of eluate were used for titration.
The remaining 145 µL were transferred to a 96 deepwell plate and incubated with 145 µL
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E. coli TG1  (OD600 = 0.5) first 30 min at 37 °C, then, 30 min at 37 °C and 650 rpm to
infect the phage particles. 1 mL 2x YT-GA was added and incubated for 1 h at 37 °C at
650 rpm, then, add (1 • 1010 cfu) M13KO7 helperphage. Again the infected bacteria were
incubated 30 min at 37 °C and 30 min at 37 °C and 650 rpm before a centrifugation for 10
min at 3220 xg was done. The supernatant was discarded and the pellet resuspended in
fresh 2x YT-AK. The phage antibodies were amplified overnight at 30 °C and 650 rpm.
For the selection of antibodies,  three panning rounds were needed.  In each round, the
washing procedures had to be intensified (20x in 2. panning round and 30x in 3. panning
round). After the third panning round, the titerplate was used to select monoclonal antibody
clones.
2.2.9.2 Panning in solution
For the panning procedure the antigen was biotinylated. 100 ng of the biotinylated antigen
was preincubated in 1.5 mL low Protein binding tube with 2 % BSA-PBS on an overhead
shaker. After 2 h, magnetic streptavidin beads were given to the tube and incubated for
further 30 min. The tube were placed 5 min on a magnetic rack and the supernatant was
discarded. The streptavidin beads were washed 10 times with 0.8 mL PBST. Bound phage
were eluted with trypsin (10 µg/mL) at 37 °C and 5 µL were used for titration.
The remaining 145 µL were transferred to a 96 deepwell plate and incubated with 145 µL
E. coli TG1  (OD600 = 0.5) first 30 min at 37 °C, then, 30 min at 37 °C and 650 rpm to
infect the phage particles. 1 mL 2xYT-GA was added and incubated for 1 h at 37 °C at
650 rpm, then, add (1 • 1010 cfu) M13KO7 helperphage. Again the infected bacteria were
incubated 30 min at 37 °C and 30 min at 37 °C and 650 rpm before a centrifugation for 10
min at 3220 xg was done. The supernatant was discarded and the pellet resuspended in
fresh 2x YT-AK. The phage antibodies were amplified at 30 °C overnight and 650 rpm.
For the selection of antibodies, three panning rounds were performed. In each round, the
washing procedures had to be intensified (20x in 2. panning round and 30x in 3. panning
round). After panning round three, the phage were again incubated with TG1 to produce
antibody phage for performing a phage ELISA.
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2.3 Molecular methods
2.3.1 Agarose gel electrophoresis
Gel electrophoresis separates DNA fragments due to their size and conformation. Therefor,
an agarose gel consisting of 1 % (w/v) agarose in TAE buffer was prepared. Ethidium
bromide was added to the gel in a final amount of 1 µg. The DNA samples were mixed
with  6 x DNA loading dye  (Fermentas)  and GeneRulerTM 1kb Plus  DNA Ladder  Mix
(Fermentas) was used as a size standard. A voltage of 100 – 120 V and a current of 400 mA
was applied for 25 – 35 min. Due to the intercalating ethidium bromide, the DNA could be
detected under UV light after electrophoresis. 
2.3.2 Extraction of DNA from agarose gel
For extraction of DNA fragments after separation in gel electrophoresis, the fragment was
cut out with a scalpel. Afterwards, the gel fragment was purified with the NucleoSpin®
Gel and PCR clean-up-Kit (Macherey & Nagel).
2.3.3 Plasmid DNA preparation
Plasmid  DNA was  prepared  from  E. coli using  a  kit  (Macherey  &  Nagel,  Germany)
depending on the  culture  volume.  For  5 mL  E. coli culture  the  NucleoSpin® Plasmid
EasyPure kit was used with 30 – 50 µL elution buffer or ddH2O for elution.
For higher culture volume (50 – 100 mL) the NucleoBond® Xtra Midi-Kit was used with
200 – 500 µL elution buffer or ddH2O for elution.
2.3.4 Determination of DNA concentration and purity
Concentration and purity of DNA were determined by measuring the absorbance at 260 nm
and 280 nm. For a pure DNA solution, an A260nm of 1 corresponds to a concentration of
dsDNA of 50 µg/mL. For a ratio of A260nm/A280nm = 1.8 – 2.0, the DNA can be considered to
be pure.
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2.3.5 Restriction digestion and dephosphorylation of DNA
For  enzymatic  DNA digestion  restriction  endonucleases  purchased  from New England
Biolabs  (NEB,  USA)  were  used.  Reaction  buffers  and  incubation  temperatures  were
chosen according to the manufacturer’s instructions. Digestion was done for 1 – 4 h at
37 °C or for up to 16 h at 16 °C and was followed by heat inactivation of the restriction
enzymes (20 min, 65 °C or 80 °C).
To avoid re-ligation of the digested vector DNA, the 5’-phosphate groups of the linearized
plasmid were removed prior to ligation. For dephosphorylation 1 µL CIP (calf intestine
phosphatase) was added for 30 – 60 min at 37 °C. Afterwards, purification was done with
NucleoSpin®  Gel  and  PCR  Clean  up-Kit  (Macherey  &  Nagel)  according  to  the
manufacturer’s instructions.
2.3.6 Ligation of DNA-fragments
DNA ligation was performed using T4 DNA ligase (NEB) at room temperature for 1 – 4 h
or at 16 °C overnight. A molar ratio of vector to insert of 1:3 was chosen:
Insert (ng)= 3 ⋅ Vector(ng)⋅size Insert (bp)
sizeVector (bp)
If the vectors pCSE2.7-hIgG1-Fc-Xp or pHAL51 were used an additional AscI restriction
step was performed after ligation. Therefor, 1 µL AscI-HF was added to the ligation and
incubated for 30 min at 37 °C.
After  ligation,  the mixture was heat inactivated at  60 °C for 10 min and was used for
transformation of competent E. coli cells.
2.3.7 Sequencing of DNA
All plasmids derived by cloning via PCR were sequenced by SeqLab (Göttingen, DE).
Therefor, 1.2 µg purified plasmid was premixt with 2.5 µL sequencing primer (10 mM).
The  analysis  of  all  sequencing  results  was  done  using  the  programs  MultAlign  and
VBASE2.
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2.3.8 Generation of bacterial and mammalian expression vectors
Two  bacterial  (pHAL51  and  pHAL52)  and  one  mammalian  (pCSE2.7-hIgG1-Fc-Xp)
expression vector were constructed that have addition restriction sites in the cloning site.
The vectors pHAL51 and pHAL52 derived from the vector pHAL30. Both vectors have an
AscI restriction site in the VL stuffer and pHAL52 has an additional SalI restriction site in
the VH stuffer.
The vector pCSE2.7-hIgG1-Fc-Xp derived from pCSE2.6-hIgG1-Fc-Xp and has an  AscI
restriction site between the NcoI and NotI restriction site.
The new stuffer were ligated into the NcoI and NotI restricted vectors. The used stuffers are
shown in table 13.
Table 13: Sequences of new generated expression vector
Vector Stuffer 5’ — 3’
pHAL51 CTAACTAAGGCGCGCCTCTGA
pHAL52 CTAGTCGACTAACTT
pCSE2.7-hIgG1-Fc-Xp CTAACTAAGGCGCGCCTCTGA
2.3.9 Amplification of DNA-fragments by PCR
For amplification of DNA polymerase chain reaction (PCR) was used. All oligonucleotides
used in this study are listed in supplemental table 31.
2.3.9.1 PCR to amplify DNA-fragments with restriction sites
For cloning into IgG vectors new restriction sites were added to the ends of the inserts by
PCR.  Therefor,  oligonucleotide  primers  were  designed.  The  mixture  for  PCR and  the
protocol is given in table 14 and 15.
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Table 14: Mixture for PCR
Amount Components
10 µL 5x Phusion HF Buffer
1 µL 10 mM dNTPs
2.5 µL 10 mM Primer I
2.5 µL 10 mM Primer II
0.5 µL Phusion Polymerase
5-10 ng DNA 
to 50 µL ddH2O
Table 15: Protocol PCR
Temperature Time
98 °C 30 sec
98 °C 20 sec
30x56 °C 30 sec
72 °C 30 sec (3-4 kb/min)
72 °C 8 min
16 °C ∞
2.3.9.2 Colony-PCR 
For colony PCR a bacteria colony was used as template for DNA amplification. This PCR
was used to screen single colonies after cloning, for detection of inserts and insert rates.
The mixture for PCR and the protocol is given in table 16 and 17.
Table 16: Mixture for colony-PCR
Amount Components
2 µL 5x GoTaq Buffer
0.8 µL 25 mM MgCl2 
0.2 µL 10 mM dNTPs
0.5 µL 10 mM Primer I
0.5 µL 10 mM Primer II
0.05 µL GoTaq
to 10 µL ddH2O
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Table 17: Protocol colony-PCR
Temperature Time
95 °C 2 min
94 °C 15 sec
25 x56 °C 20 sec
72 °C 1:20 - 2:30 min (1 kb/min)
72 °C 3 min
16 °C ∞
2.3.10 Generation of an immune antibody gene library
For the generation of a  human immune library against  diphtheria  toxin blood of  three
persons who have been regularly boost-vaccinated was collected 7 days after they received
a boost vaccination of diphtheria toxin and tetanus. The peripheral blood mononuclear cells
(PBMC) were extracted from the blood via Ficoll® and RNA isolated with Trizol and a
Trizol RNA purification kit. For the B-cell sorted libray, B-cells were stained with mouse
α-CD138 (FITC conjugated) antibody and sorted via FACS. Also the RNA of the sorted
B cells were extracted.  The RNA was converted into cDNA. The cDNA was amplified
with specific primers for the VH chain, primers for κ light chain and primer for λ light
chain. These PCR products were again amplified with primers adding a restriction site for
further cloning into the E. coli expression vector pHAL51. First the light chain was cloned
with  the  restriction  sites MluI and  NotI,  second  the  VH  chain  was  cloned  with  the
restriction sites HindIII and NcoI. The efficiency of cloning was tested with a colony PCR
and the rate of complete scFv were determined. The libraries were further packaged with
hyperphage or glycerine (20 % (v/v)) was added and stored at – 80 °C.
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2.4 Protein biochemical methods
2.4.1 Purification of antibodies with protein A
In  EXPI293F  cell  produced  scFv-Fc  and  IgG  were  purified  from  supernatant  with
protein A. All buffers and the distilled water were filtered (0.45 µm) and degassed. The cell
culture medium containing the antibodies was centrifuged at 750 xg for 10 min at 4 °C and
was filtered as well.
2.4.1.1 Protein A purification in 24 well plate
For affinity chromatography in 24 well vacuum filtration plate (10 mL Uniplate PP, 10 mL
Unifilter, 10 μm melt blown PP) with a MabSelectTM SuRe Protein A affinity matrix (GE
7701-5110; GE 7700-9917; GE 17-5438-01; Whatman, Munich, Germany) was used. The
wells  were  equilibrated  with  buffer  and  afterwards  loaded  with  filtered,  antibody-
containing supernatant. The supernatant passed the wells by gravity flow. The wells were
washed  with  binding  buffer  and  the  bound  antibodies  were  eluted  with  elution  buffer
(pH 3) in three steps. First, 750 µL of protein A elution buffer was added to the matrix and
incubated  for  5  minutes  with  vacuum  applied.  The  second  and  third  elution  were
performed with 500 µL elution buffer. Afterwards, the buffer was exchange to PBS either
by dialysis or by the use of Zeba™ Desalt Spin column and the purified antibodies were
stored for short time at 4 °C or for long time storage aliquoted and stored at -20 °C.
 
2.4.1.2 ProfiniaTM- purification system
For affinity chromatography in ProfiniaTM- purification system (BioRad) a 1 mL Protein A
BioScale Mini UNOsphere SUPrA column (BioRad) and a 10 mL BioScale Mini Bio-Gel
P-6 Desalting cartridge (BioRad) were used. The columns were equilibrated with buffer
and afterwards loaded with filtered, antibody-containing supernatant with a flow rate of
0.5 mL/min. The column was washed with binding buffer and the bound antibodies were
eluted with elution buffer and desalted. The collected antibodies were buffered in PBS and
stored for short time at 4 °C or for long time storage aliquoted and stored at -20 °C.
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2.4.2 Purification of proteins with IMAC
Recombinant proteins containing a HIS-tag were purified using immobilized metal  ion
affinity chromatography (IMAC). The bacteria culture was centrifuged at 10,000 xg for
15 min at 4 °C. Then, the pellet was resuspended in binding buffer and sonicated 3 times
for 2 min with pulsed cycles. Afterwards, the suspension was centrifuged at 16,000 xg for
10 min at 4 °C and the supernatant was loaded to a support column containing 1 mL of
Sepharose (activated with 0.1 M NiSO4). The column was washed with washing buffer
until a OD280 ≈ 0 of the flow-through was reached. Then, the bound antibodies were eluted
with elution buffer. The buffer was exchange to PBS by dialysis and the purified proteins
were stored for short time at 4 °C or aliquoted and stored at -20 °C for long time.
2.4.3 Determination of protein concentration
Concentration of protein was determined by measuring the absorbance at 280 nm via UV/
VIS spectrometry using Nanodrop ND1000. The molecular weight and molar extinction
coefficient (according to Geneious 4.8.5) were considered in the calculation of the protein
concentration.
2.4.4 Antigen-enzyme-linked immunosorbent assay (ELISA)
In an ELISA (enzyme-linked immunosorbent assay) antigen-antibody specific interactions
are detected via an enzymatic color reaction.
Nunc MaxiSorp microtiter plates were coated with 100 ng target protein or 100 ng BSA in
100 µL coating buffer per well at 4 °C overnight. The plate was washed three times with
PBS-T using an ELISA washer and blocked with 350 µL milk-PBS-T per well for 1 h at
RT.
2.4.4.1 Indirect antigen-ELISA
For the indirect ELISA, 50 µL soluble antibody and 50 µL blocking solution per well is
incubated for 1 h at RT. The plate was washed three times with PBS-T using an ELISA
washer and 100 µL primary antibody mouse α-c-Myc (1:50 in blocking solution) were
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added per well for 1 h at RT. Afterwards the plates were washed again. Goat α-mouse IgG
(Fc-specific) antibody conjugated with horse radish peroxidase (HRP, 1:50,000) was used
as secondary detection antibody and was incubated for 1 h at RT. Unbound antibodies were
removed  by  additional  washing  steps.  Bound  antibodies  were  visualized  with  TMB
substrate  (20  parts  TMB  solution  A and  1  part  TMB  solution  B  were  mixed).  After
stopping the reaction by adding 100 µL stopping solution, absorbance at 450 nm with a
620 nm reference was measured in an ELISA reader.
2.4.4.2 Titration-ELISA
The  titration  ELISA was  performed  like  the  indirect  antigen  ELISA.  For  the  titration
ELISA a  serial  dilution  was  made  in  blocking  solution  starting  with  1  µg  antibody.
Afterwards, the dilution were prepared in  (√10)−1 - steps. 100 µL of each dilution was
added per well and incubated for 1 h at RT. The plate was washed 3 times with PBS-T.
Goat α-human IgG (Fc-specific) antibody conjugated with horse radish peroxidase (HRP,
1:70,000)  was used as secondary detection antibody and was incubated for 1 h at  RT.
Unbound antibodies were removed by additional washing steps. Bound antibodies were
visualized with TMB substrate (20 parts TMB solution A and 1 part TMB solution B were
mixed). After stopping the reaction by adding 100 µL stopping solution,  absorbance at
450 nm with a 620 nm reference was measured in an ELISA reader.
2.4.4.3 Phage ELISA
For the phage ELISA 50 µL phage antibodies and 50 µL blocking solution per well were
incubated in the first well followed by a serial 1:2 dilution up to 1:2000 for 1 h at RT. The
plate was washed three times with PBS-T using an ELISA washer and 100 µL primary
antibody goat α-M13 (pVIII) conjugated with horse radish peroxidase (HRP, 1:40,000 in
blocking solution) were added per well for 1 h at RT. Unbound antibodies were removed
by  additional  washing  steps.  Bound  antibodies  were  visualized  with  TMB  substrate
(20 parts TMB solution A and 1 part TMB solution B were mixed). After stopping the
reaction  by  adding  100  µL stopping  solution,  absorbance  at  450  nm  with  a  620 nm
reference was measured in an ELISA reader.
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2.4.5 SDS-polyacrylamid-gelelectrophorese (SDS-PAGE) 
Sodium  dodecyl  sulfate  polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was  used  to
separate proteins according to their electrophoretic mobility. The running and stacking gel
(table 18) were cast between 2 glass plates separated by a 0.75 mm spacer. The running gel
was prepared and overlaid with ddH2O. After gel polymerization, the ddH2O was removed,
the stacking gel was cast and a comb was inserted.
Table 18: Recipe for running and stacking gel for a SDS-PAGE
Components running gel 
(12 %)
stacking gel 
(4 %)
ddH2O 1.3 mL 1 mL
30 % Acrylamid (Rotiphorese) 1.6 mL 0.26 mL
1.5 M Tris (pH 8.8) 1.0 mL -
1 M Tris (pH 6.8) - 0.2 mL
10 % SDS 40 µL 15 µL
10 % APS 40 µL 15 µL
TEMED 2 µL 2 µL
The protein samples were mixed with 5x Laemmli’s sample buffer and were boiled for
10 min at  95 °C. Afterwards, a protein standard and samples were loaded onto the gel.
Electrophoresis was performed at 200 V and 400 mA per gel for 45 min followed by either
staining (Coomassie or silver) or Western blot analysis.
2.4.6 Coomassie staining of SDS gels
Proteins  on  SDS  gels  were  stained  with  Coomassie  staining  solution  that  dyes  non-
covalently  the  amino  and carboxyl  groups  of  proteins.  To destain  the  gels,  destaining
solution  was  applied  until  only  the  protein  bands  were  left  clearly  visible.  For
documentation, the gels were scanned with a computer scanner.
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2.4.7 Silver staining
SDS gels can be stained by silver ions that are taken up by negatively charged side chains
of proteins. This interaction can then be visualized through color change by reduction of
the silver  ions to silver leaving a black stain.  Proteins on SDS gels were fixated with
50 mL fixation solution for 1 h. After 3 times washing with 50 % ethanol for 20 min, the
gel was incubated in sodium thiosulfate for 1 min. Three times washing for 20 s with H2O
followed by 1 – 5 min staining with develop solution. Again, washing with water 2 times
for 2 min and subsequently stopping the reaction with stop solution. For documentation the
gels were scanned with a computer scanner.
2.4.8 Western Blot and immuno staining
A  semi-dry  Western  blot  was  performed  to  transfer  proteins  from  SDS  gels  onto
polyvinylidene fluoride (PVDF) membranes. Blotting papers were pre-soaked in blotting
buffer and stacked together with the ethanol-activated PVDF membrane and the SDS gel.
Transfer of the proteins was performed at 20 V for 30 min.
After  Western blotting,  the membrane was blocked with M-PBST for  60 min at  room
temperature to limit unspecific antibody binding and then washed with PBST. Detection of
proteins  was  performed  indirectly  via  specific  primary  antibody  followed  by  AP-
conjugated secondary antibody. Antibodies were diluted in M-PBST and incubated for 1 h
at room temperature. After washing with PBST and substrate buffer, bound antibodies were
visualized in NBT/BCIP (NBT and BCIP solution 1:100 in substrate buffer). Finally, the
membrane was washed with water and dried. For documentation the blots were scanned.
2.4.9 Epitope mapping
For epitope mapping a PepSpot membrane from JPT Peptide Technologies GmbH (Berlin,
DE) was used. The amino acid sequence was cut in 15 amino acid long pieces with an
overlap  of  12  amino  acids  and  covalently  bound  to  a  cellulose-β-alanine-membrane.
Methanol  activation  of  the  membrane  was  followed  by  three  washing  steps  and  2 h
blocking  in  2 % M-TBST.  The  scFv-Fc for  the  analysis  was  diluted  to  1 µg/mL with
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M-TBST and incubated for 3 h at RT. After three washing steps with TBST the membrane
was incubated with the secondary antibody goat α-human Fc HRP conjugated (dilution
1:70,000 in M-TBST). After three times washing with TBST the membrane was incubated
with SuperSignal West Pico Chemiluminescent Substrate and the chemiluminescence was
analyzed in a Gel Doc XR+ System (Bio-Rad).
2.4.10 Size exclusion chromatography (SEC)
The  aggregation  behavior  of  IgG  antibodies  was  analyzed  with  size  exclusion
chromatography (SEC). A SuperdexTM 200 Increase 10/300 GL column was used with the
Äkta purifier system. An amount of 150 µg IgG were analyzed with a flow rate of 0.5 mL/
min.  The  absorption  at  280 nm  was  measured  and  the  molecular  weight of  the  IgG
antibody determined by using a standard curve.
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2.5 Cell biological methods
2.5.1 Cultivation of EXPI293F cells
The  suspension  cell  line  EXPI293F  (EXPI)  was  cultured  in  serum-free  F17  medium
supplemented with 7.5 mM L-glutamine and 0.1 % Pluronic-F68. They were incubated at
37 °C, 5 % CO2 and 110 rpm.
2.5.2 Transient transfection of EXPI293F cells 
Two  days  before  transient  transfection  EXPI293F  cells  were  seeded  with
0.5 • 106 cells/mL. The cells had a concentration of 1.5 • 106 cells/mL with a vitality over
90 %.  The  used  amounts  of  cells,  DNA and  transfection  reagent  PEImax  (40 kDa,
1 mg/mL, Polysciences, Warrington, USA) are shown in table 19. PEImax and DNA were
mixed  well  and  incubated  for  30  min  before  adding  it  to  the  EXPI293F  cells.  The
antibodies were produced over 7 days. After 2 days of transfection cells were fed with
HK-TF (5 parts) and HK-FS (1 part) to double the volume.
Table 19: Transfection mix according to scale
Cultivation Flask EXPI293F volume
End volume 
after feeding
Amount 
DNA (µg)
Amount 
PEImax (µL)
small scale 25 mL Sarstedt Flask 5 mL 10 mL 5 25
large scale 125 mL Erlenmeyer flask 25 mL 50 mL 25 125
micro scale 96 deepwell plate 0.4 mL 0.8 mL 0.4 2
2.5.3 Cultivation of Vero cells
The adherent cell line Vero(WHO) was cultured in EMEM medium, supplemented with
5 %  FCS,  0.015 M  HEPES, 2 mM L-glutamin,  0.1 %  Glucose  and  100 µg/mL
penicillin/streptomycin. Cells were incubated at 37 °C, 5 % CO2 and humidity of 96 %. To
passage them, cells were washed with PBS and incubated with trypsin/EDTA until they
detached  from  the  tissue  flask.  The  cells  were  seeded  into  fresh  flasks  containing
appropriate volume of pre-heated medium at 37 °C.
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2.5.4 Freezing and thawing of cells
For  long-term  storage,  the  cells  were  harvested  as  described  above,  centrifuged,
resuspended in freezing medium  (10 % DMSO and 90 % EMEM with all supplements)
and transferred to cryo tubes. To allow a slow and gradual freezing, tubes were stored at
-80 °C  in  a cell  cryo  container  (Mr.  FrostyTM,  Thermo Fisher  Scientific)  for  one  day.
Afterwards, the tubes were transferred to liquid nitrogen.
For thawing, frozen cells were incubated in a 37 °C water bath and right upon thawing
added  to  10 mL  cold  EMEM  medium.  Cells  in  DMSO  containing  medium  were
centrifuged for 10 min at  250 xg and 4 °C. The medium was discarded and cells  were
resuspended in fresh, 37 °C warm medium and seeded in an appropriate cell culture flask.
2.5.5 Counting cells
To distinguish between living and dead cells, cells in suspension were mixed with trypan
blue,  a  dye  that  only  stains  dead  cells.  Living  and  dead  cells  were  counted  in  a
hemocytometer (Countess II FL, life technologies, Waltham, USA). The cell density (cells/
mL), the total number of cells and the percentage of living cells (vitality) were calculated
by the cell counter.
2.5.6 Diphtheria toxin titration to determine 4x MCD
To determine the minimal cytopathic dose diphtheria toxin was titrated in a 96 cell culture
plate. Therefore, wells in row A and H and in column 12 are not used (blanks). 50 µL
EMEM medium was added to all wells except column 1. 100 µL of the toxin working
stock solution was added to the appropriate wells in column 1. A doubling dilution (50 µL)
was performed across the plate down to column 10. Then, 50 µL EMEM medium was
added to all wells to bring volume to 100 µL. 50 µL of the appropriate Vero cell suspension
(4 • 105 cells/mL) was added to all wells except the blanks. The plate was equilibrated for
1 h in a CO2 incubator, sealed and further incubated for 6 days at 37 °C.
After 6 days, the seal was removed and the MTT assay performed. 5 mg MTT/mL in PBS
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was prepared and sterile filtrated through a 0.2 µm filter. 10 µL MTT solution was added to
each well  and incubated at  37 °C, 5 % CO2 for 4 h.  All  supernatant was removed and
100 µL extraction buffer was added to each well. After 1 day of incubation at 37 °C, the
plate was measured at an absorption of 570 nm.
The geometric mean OD of the untreated Vero cells were calculated and then the 50 % of
the geometric mean was determined. The first concentration of the wells of a geometric
mean OD lower than the 50 % untreated Vero cells were determined. This concentration is
the  minimal  cytopathic  dose  (MCD)  and  was  multiplied  with  factor  four  to  get  the
4x MCD. This 4x MCD was used as a constant amount of toxin for the toxin neutralization
assay with Vero cells.
2.5.7 Toxin neutralization assay with Vero cells
The Vero cell assay is an in vitro toxin neutralization test (TNT) which measures the ability
of antibodies to protect Vero cells from a cytotoxic dose of diphtheria toxin. The TNT Vero
cell assay was performed according to in-house protocols from NIBSC (London, UK). The
first  WHO International Standard (IS) for human diphtheria antitoxin was included as a
reference antitoxin and, if available, an equine therapeutic DAT product was included for
comparison.
The candidate  antibodies  were titrated  with pre-dilution  starting  undiluted  or  at  1:2  or
1:500  in  Vero  cell  medium.  Occasionally,  a  pre-dilution  starting  at  1:100,000  was
necessary.
A 96 well cell culture plate was used to dilute the antibodies. 100 µL of antitoxin reference,
comparator  or  antibody  were  added  to  wells  A1-H1.  50  µL EMEM was  added  to  all
remaining wells except control without DT in column 11 which get 100 µL. Then, perform
doubling dilutions across plate up to column 10 and add  50 µL of toxin preparation 4x
minimal cytopathic dose (4x MCD) to all wells – except control without DT. To occur
toxin neutralization, the plate was covered with a lid and left for 1 h at RT. 50 µL of the
appropriate Vero cell suspension (4 • 105 cells/mL) was added to all wells. The plate was
equilibrated for 1 h in a CO2 incubator, sealed and further incubated for 6 days at 37 °C.
After 6 days, the seal was removed and the MTT assay performed. 5 mg MTT/mL in PBS
38
2 Materials and Methods
was prepared and sterile filtrated through a 0.2 µm filter. 10 µL MTT solution was added to
each well and incubated at 37 °C, 5 % CO2 for 4 hour. All supernatant was removed and
100 µL extraction solution was added to all wells. After 1 day of incubation at 37 °C, the
plate was measured at an absorption of 570 nm.
The geometric mean OD of the untreated Vero cells were calculated and then 50 % of the
geometric mean determined. The last concentration above the 50 % untreated Vero cells
were determined. This concentration is the minimal effective dose 50 % (MED50%) of an
antibody.
2.5.8 Extraction of PBMC
EDTA-treated blood was mixed to equal parts with FACS buffer and slowly added over a
layer of Ficoll Parque, centrifuged at 400 xg for 30 min at RT with no breaks applied to
stop. The PBMCs are in the lymphocyte layer between the plasma and the Ficoll Parque.
This layer was carefully removed with a pipette and transferred in FACS buffer. PBMCs
were washed three times with FACS buffer by centrifugation for 10 min at 300 xg. Amount
of PBMC after the last resuspension step in FACS buffer was determined.
2.5.9 Flow cytometry of PBMC
A total  of  1 • 107 cells  were  transferred  into  1.5  mL tubes.  Cells  were  stained  with
α-CD138 (FITC) or α-IgG Fc (APC). Therefor, cells were centrifuged at 300 xg, 10 min at
4 °C and the pellet was resuspended in 100 µL of primary antibody dilution and incubated
for  1 h  on  ice  in  the  dark.  Afterwards,  cells  were  washed  twice  with  FACS  buffer,
resuspended  in  1000 µL FACS  buffer  and  analyzed  by  flow  cytometry  using  a  Sony
SH-800 (San Jose, USA) with two lasers (488 nm and 638 nm) and appropriate detectors
for detection of FITC and APC. For each sample 104 events were counted and resulting
data was analyzed using Sony analysis software.
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3.1 Antibody gene extraction for an immune library
Three  persons  were  regularly  boost-vaccinated  with  dDT,  a  diphtheria  and  tetanus
combination. After seven days, EDTA-treated blood samples were collected and PBMCs
extracted  with  Ficoll.  An average  concentration  of  4.74 • 107 PBMC/mL were  counted.
Two immune libraries were constructed. For the first library the total PBMCs were used,
the RNA was isolated and an average concentration of 209 ng/mL was measured followed
by cDNA synthesis. This first immune library was called VJN. For the second library the
fresh prepared PBMCs were stained with a florescence conjugated CD138+ antibody to
stain the antibody-producing B cells.  In the next step the positively stained cells  were
selected via FACS (figure 4).
A B C
Figure 4: FACS analysis of PBMC for selection of CD138+ cells. Shown is the pre-analysis with
10,000 cells before the sorting started. Cell Sorting with CD138+ (FITC) and IgG Fc (APC).
The erythrocytes  and debris  (orange),  lymphocytes  (red)  and monocytes  (purple)  were
gated in a forward-sideward scatter plot in the FACS software (figure 4A). Lymphocytes
were present with 32.5 % in the PBMC mixture. Monocytes were present with 13.3 %. A
goat α-CD138 antibody conjugated with FITC was used to stain plasma cells in the PBMC
mixture. Lymphocytes were further selected via FACS for CD138+ cells (figure 4B). As a
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control  Fc  presenting  cells  in  the  PBMCs were  stained  with  an  α-IgG Fc  and  in  the
lymphocyte fraction 22.11 % Fc positives cells were detected (figure 4C). Afterwards, the
sorting was started and over 88,000,000 PBMCs were analyzed and 2,501 CD138+ cells
were sorted (= 0.003 %). These selected cells were further used for library construction.
The RNA was extracted and a concentration of 7.7 ng/µL was measured. Afterwards a
reverse transcription was performed to obtain cDNA. This second immune library was
called the CD138+ library.
3.2 Library construction
The cDNA from total PBMC and CD138+ sorted cells were used to amplify the VH and VL
gene sequences. The VH and VL were cloned into the phage display vector pHAL51. The
cDNAs derived from the blood of the persons were kept separated for the total PBMC
library  and also lambda and kappa light  chains  were  kept  separated.  The cloning was
performed in two steps: firstly, the VL cloning with the restriction sites MluI and NotI and
secondly, the VH cloning with the restriction sites NcoI and HindIII were performed. The
diversity over all sub-libraries were between 1,31 – 3,45  • 108 individual clones per mL
with an insert rate of 73 – 95 % (table 20).
Table 20: Overview of all constructed immune libraries with titer (cfu/mL) and insert rate (%).
Library type Sub-Library name Titer (cfu/mL) Insert rate (%) 
Immune Library V λ Library 3.45 • 108 90.9
Immune Library V κ Library 2.39 • 108 95.4
Immune Library J λ Library 2.18 • 108 86.4
Immune Library J κ Library 1.75 • 108 72.7
Immune Library N λ Library 2.00 • 108 81.8
Immune Library N κ Library 1.31 • 108 81.8
Immune Library sorted CD138+ λ Library 4.00 • 108 86.9
Immune Library sorted CD138+ κ Library 3.70 • 108 78.2
Subsequently, the libraries were packaged with hyperphage to present the scFv antibody
coupled to the pIII on the phage. For the packaging, the sub-libraries of the total PBMC
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library were mixed to receive the VJN library as a pool. The lambda and kappa libraries
were still kept separate. This resulted in phage titers of 7.4 • 1012 cfu/mL for VJN lambda,
7.2 • 1012 cfu/mL for VJN kappa, 2.6 • 1012 cfu/mL for CD138+ lambda and 6.0 • 1012 cfu/
mL for CD138+ kappa. The packaging was further analyzed in a pIII stained western blot
(figure 5).
All libraries showed the native pIII (60 kDa) and the pIII-antibody-fusion (90 kDa).
3.3 Selection of monoclonal antibodies
For antibody selection three different libraries were used: the naive HAL9/HAL10 libraries
and the two constructed immune libraries VJN and CD138+. Two different strategies were
chosen for selecting antibodies: on the one hand, the antigen is immobilized on a plate and
on the other hand, the antigen is biotinylated and free in solution. The unnicked diphtheria
toxin produced in  Corynebacterium diphtheriae (List Biological Laboratories, Inc.) was
chosen as antigen in all strategies. With these 2 methods 660 antibodies were selected in
total.
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Figure  5:  Immunoblot  of  hyperphage
packaged immune libraries. 5  • 108 cfu
used.  Detection  with  α-pIII  antibody.
L=lambda, K = kappa light chain. 
pIII
pIII antibody fusion
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3.3.1 Panning on plates
171 scFv antibodies were isolated from the three libraries (one naive and two immune 
libraries) using the strategy of immobilization on plate (table 21).
Table 21: Number of scFv developed from a panning with immobilized antigen
Library 
type
Library 
name
No. of DT 
binder
scFv after 
BstNI 
digestion
No. of 
lambda 
scFv
No. of 
kappa 
scFv
Unique 
scFv after 
sequencing
Unique 
VH 
chains
Naive
HAL9/ 
HAL10
39 29 29 0 29 24
Immune VJN 67 52 42 10 51 34
Immune CD138+ 65 56 44 12 50 10
Sum: 171 137 115 24 130 68
These antibodies were further analyzed regarding their genetic information. First, a BstNI
digestion was done to identify identical clones by identical patterns during electrophoresis
(data not shown). A number of 137 different clones were identified after BstNI digestion.
Second, the 137 antibodies were sequenced to confirm the result. 130 of these scFv were
identified as unique after sequencing (supplemental table 32).
For all further characterizations the selected scFv antibodies against diphtheria toxin were
converted  in  a  IgG-similar  scFv-Fc  format.  Therefor,  the  gene  sequence  of  the  scFv
antibodies  were  cloned  into  the  pCSE2.7-hIgG1-Fc  expression  vector.  The  transient
transfection and later the production were performed in 96 deepwell plates in EXPI293F
cells over 7 days. The produced antibodies were secreted in the growth medium and the
supernatant  was  used  for  performing  the  neutralization  assay.  A serial  dilution  of  the
supernatant was incubated with a constant amount of diphtheria toxin (4x MCD) and after
6 days of incubation with Vero cells, the cytopathic effect was measured with an MTT
assay. The produced antibodies were analyzed regarding their  neutralization efficacy in
neutralization assay (figure 6 and supplemental figure 25 and 26).
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Cells  reaching  a  neutralization  effect  above  50 %  (red  dotted  line)  were  regarded  as
neutralizers. In the exemplary figure  6, the colored antibodies ewe192-B5 (green square)
and  ewe192-C11  (nude  diamond)  were  considered  neutralizers.  All  other  gray  colored
antibodies were not further analyzed. The antibody ewe192-B5 (green open square, dotted
line) was identified as a good neutralizer in a pre-test and was used further purified as
positive control in all neutralization assays. In this assay, 22 scFv-Fc antibodies showed a
neutralization in  the assay.  These 22 scFv-Fc antibodies  were further  analyzed.  The V
genes for the 22 selected antibodies are shown in table 22.
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Figure  6: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
shown as green dotted line. The threshold for neutralization is shown as red dotted line (50% of
untreated Vero cells). The antibody A2 (red, open symbol and dotted line) is considered as negative
control, ewe192-B5 (green, open symbol and dotted line) as positive control (derived from a pre
test). scFv-Fc antibodies shown in colored and gray symbols were further analyzed. Mitochondrial
activity was measured with an MTT assay after 6 days at OD570nm.
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Table 22: V genes of 22 scFv clones selected for further analysis
Name of 
Antibody 
clone
VH VL
V D J V J 
ewe191-A7 IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
ewe191-A9 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
ewe191-C1 IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV3-15*01 IGKJ4*01
ewe191-C10 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*01
ewe191-C11 IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
ewe191-C12 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*01
ewe191-D1 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV1-47*02 IGLJ3*01
ewe191-E12 IGHV5-51*01 IGHD3-16*01 IGHJ5*02 IGLV1-44*01 IGLJ1*01
ewe191-H8 IGHV3-23*04 IGHD3-10*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
ewe191-H10 IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*02
ewe192-A6 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ5*01
ewe192-B5 IGHV4-34*01 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
ewe192-C11 IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV8-61*01 IGLJ3*01
ewe192-D7 IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-23*03 IGLJ3*02
ewe192-D8 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV3-21*02 IGLJ3*02
ewe192-E4 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
ewe192-F6 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ1*01
ewe192-F11 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV1-40*01 IGLJ3*01
ewe192-G12 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ3*01
ewe192-H7 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-23*03 IGLJ3*02
ewe192-H8 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3D-15*01 IGKJ5*01
ewe192-H11 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-11*01 IGLJ3*02
One antibody contained a stop codon in the sixth position of the VH chain (ewe192-B5).
For this antibody, the germline was analyzed which confirmed that IGHV4-34*01 has the
amino acid glutamine (Q) at position 6. After PIPE cloning the stop codon was changed to
the amino acid Q. Further, this antibody will be called ewe192-B5(P).
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3.3.2 Panning in solution
For the strategy of panning in solution biotinylated antigen was used and pulled down with
magnetic  streptavidin  beads.  Here,  only  the  immune  libraries  were  used  for  antibody
selection, because the naive library did not result in neutralizing antibodies in the former
plate panning. To monitor the enrichment of diphtheria toxin binding phage by panning in
solution, a phage ELISA was performed with phage particles of all three panning rounds
(figure 7).
An enrichment of binders to diphtheria toxin and biotinylated diphtheria toxin was shown
over 3 panning rounds. Best binding capability was achieved after 3 panning rounds (green
lines). Biotinylated  DT was  the  antigen  used  for  the  panning in  solution.  All  immune
libraries bound the DT (filled symbol, solid line) as well as the biotinylated DT (filled
symbol, dotted line). No cross reactivity to 2R2t (open symbol, solid line) or BSA (open
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Figure 7: Titration phage ELISA with packaged antibody-phage from panning round 1 (1.P; blue),
panning round 2 (2.P; red) and panning round 3 (3. P; green). The two immune libraries (VJN &
CD138+) were analyzed,  separated by lambda and kappa.  A) VJN lambda,  B) VJN kappa,  C)
CD138+ lambda and D) CD138+ kappa. Binding was tested on diphtheria toxin (DT; filled symbol,
solid line), the biotinylated diphtheria toxin (DT-B; filled symbol, dotted line), 2R2t (non related
protein; open symbol, solid line) and BSA (negative control; open symbol, dotted line). Detected
with  goat  α  pVIII  HRP conjugated  antibody,  visualized  with  TMB substrate  and measured  at
450 nm with a 620 nm reference.
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symbol, dotted line) was observed.
The antibody pool was directly cloned in scFv-Fc format (pCSE2.7-hIgG1-Fc-xp). 384 (4x
96) scFv-Fc monoclonal  antibodies  were selected.  All  of  these antibodies  were further
produced in EXPI293F cells in 96 deepwell plates. The produced antibodies were secreted
in  the  growth medium and the  supernatant  was used for  performing the  neutralization
assay.  A serial  dilution  of  the  supernatant  was  incubated  with  a  constant  amount  of
diphtheria toxin (4x MCD) and after 6 days of incubation with Vero cells, the cytopathic
effect  was  measured  with  an  MTT  assay.  These  produced  antibodies  were  analyzed
regarding their neutralization efficacy in neutralization assay (figure  8 and supplemental
figure 27, 28, 29 and 30).
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Figure 8: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero
cells are given as horizontal green dotted line. The threshold for neutralization is given
as horizontal red dotted line (50 % of untreated Vero cells). The antibodies TM43-E10
and JöJ58B9 (red, open symbols and dotted line) are considered as negative control,
ewe192-B5  (green,  open  symbol  and  dotted  line)  as  positive  control.  scFv-Fc
antibodies shown in color and gray were further analyzed. Samples with black symbol
were not further considered. Mitochondrial activity was measured with an MTT assay
after 6 days at OD570nm.
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Cells reaching a neutralization effect above the 50 % line (red dotted line) were regarded as
neutralizers.  In  the  exemplary  figure  8,  the  colored  antibodies  ewe372-A12  (pink
diamond),  ewe372-D11 (dark  yellow diamond)  and ewe372-D12 (gray  diamond)  were
further  analyzed.  The  antibody  ewe192-B5  was  used  as  positive  control  in  the
neutralization assays (green open square, dotted line) and as negative control the antibodies
TM43-E10 (red open square, dotted line) and JöJ58B9 (red open circle, dotted line) were
used. In total, 268 scFv-Fc showed neutralization and of these, 36 scFv-Fc antibodies were
further analyzed. The V genes of these 36 scFv-Fc antibodies are shown in table 23.
Table 23: V gene analysis of 36 scFv-Fc clones selected for further analysis.
Name of 
clone
VH VL
V D J V J 
ewe371-A2 IGHV3-33*01 IGHD2-2*01inv IGHJ3*02 IGLV2-14*04 IGLJ3*01
ewe371-A6 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV3-21*01 IGLJ3*01
ewe371-B12 IGHV3-33*01 IGHD6-13*01 IGHJ4*03 IGLV1-47*01 IGLJ3*01
ewe371-D10 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*02
ewe371-D4 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV3-19*01 IGLJ3*01
ewe371-D7 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*01
ewe371-E4 IGHV3-23*01 IGHD3-10*01 IGHJ4*02 IGLV2-14*04 IGLJ1*01
ewe371-E7 IGHV5-51*01 IGHD2-2*01 IGHJ5*02 IGLV2-8*01 IGLJ3*01
ewe371-G2 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ1*01
ewe371-G4 IGHV4-34*01 IGHD5-12*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
ewe371-G8 IGHV1-3*01 IGHD2-2*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
ewe371-H1 IGHV3-23*04 IGHD3-10*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01
ewe371-H9 IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*02
ewe372-A12 IGHV1-3*01 IGHD6-19*01 IGHJ3*01 IGKV1-27*01 IGKJ4*01
ewe372-A8 IGHV1-69*04 IGHD6-13*01 IGHJ3*02 IGKV1D-39*01 IGKJ3*01
ewe372-C10 IGHV4-34*01 IGHD2-2*02 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
ewe372-C4 IGHV1-69*04 IGHD1-1*01 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
ewe372-C5 IGHV1-69*04 IGHD2-2*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
ewe372-C8 IGHV1-69*04 IGHD2-2*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
ewe372-D11 IGHV1-18*01 IGHD3-10*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
ewe372-D12 IGHV1-69*04 IGHD2-2*02inv IGHJ4*02 IGKV1D-39*01 IGKJ4*01
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Name of 
clone
VH VL
V D J V J 
ewe372-D3 IGHV4-34*02 IGHD2-15*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01
ewe372-D7 IGHV1-69*04 IGHD2-21*02 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
ewe372-D9 IGHV1-46*03 IGHD1-20*01 IGHJ4*02 IGKV1D-33*01 IGKJ5*01
ewe372-F3 IGHV1-46*03 IGHD1-20*01 IGHJ4*02 IGKV1-12*02 IGKJ4*01
ewe372-F6 IGHV3-23*04 IGHD4-17*01inv IGHJ6*02 IGKV1-5*03 IGKJ5*01
ewe372-G2 IGHV1-69*06 IGHD2-15*01 IGHJ4*02 IGKV1D-39*01 IGKJ4*01
ewe372-H1 IGHV4-34*02 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
ewe374-C9 IGHV4-34*01 IGHD5-12*01 IGHJ6*02 IGLV1-44*01 IGLJ3*01
ewe374-E6 IGHV4-34*01 IGHD5-18*01 IGHJ6*02 IGLV3-19*01 IGLJ1*01
ewe374-F7 IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-23*03 IGLJ3*02
ewe375-B8 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGKV3-20*01 IGKJ3*01
ewe375-G7 IGHV1-69*04 IGHD1-26*01 IGHJ4*02 IGKV1D-39*01 IGKJ3*01
ewe375-D2 IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ5*01
ewe375-D4 IGHV4-34*02 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
ewe375-H4 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGKV3-20*01 IGKJ3*01
Three antibodies (ewe372-C10, ewe372-D3 and ewe372-H1) contained a stop codon in the
sixth position of the VH chain. For these three antibodies, the germline was analyzed and
confirmed that IGHV4-34 has the amino acid glutamine (Q) at position six. An introduced
point mutation changed the stop codon to the amino acid Q. Additionally, it was checked
the amino acid position 7 of the VH chain. At this position the already developed antibody
ewe192-B5(P) had the amino acid serine (S) but germline analysis confirmed the amino
acid tryptophan (W) occurred at this position. Hence, two versions were developed of each
of the three antibodies and named after their seventh amino acid position ewe372-C10-S/
ewe372-C10-W,  ewe372-D3-S/  ewe372-D3-W and ewe372-H1-S/  ewe372-H1-W.  After
these modifications, 39 scFv-Fc antibodies were further analyzed.
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3.4 Characterization  of  monoclonal  antibodies  in  scFv-Fc
format
The 22 antibodies from panning on plates and 39 antibodies from panning in solution that
showed  good  neutralization  potency  were  characterized  regarding  their  binding  to
diphtheria toxin and neutralization potency in a cell based in vitro assay. Finally, a domain
mapping was  performed  to  determine  which  domain  was  recognized  by each  scFv-Fc
antibody.
3.4.1 Binding of monoclonal antibodies in scFv-Fc format
The  half  maximal  effective  concentration  (EC50)  was  determined  for  all  scFv-Fc
antibodies by performing a titration ELISA on immobilized diphtheria toxin and the non-
toxic  DT-mutant  CRM197  (figure  9).  EC50  for  diphtheria  toxin  widely  ranged  from
0.0086 µg/mL to 11.9 µg/mL. The non-toxic mutant CRM197 showed binding in the range
of 0.0108 µg/mL to 18.38 µg/mL. For better visualization, antibodies with the lowest EC50
are marked in yellow, antibodies with the highest EC50 are marked in gray (table 24).
Out  of  61  scFv-Fc  antibodies,  16  showed  a  more  than  3-fold  increased  binding  to
diphtheria toxin than to the similarly folded non-toxic DT-mutant CRM197. None of the
antibodies showed unspecific binding to BSA. All antibodies were further tested for their
neutralization potency.
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Figure  9: Titration ELISA of scFv-Fc antibodies for binding to diphtheria toxin (filled symbol,
solid  line)  and  CRM197  (non-toxic  mutant;  open symbol,  dotted  line)  with  BSA as  negative
control (line).  Detected with goat α human Fc antibody HRP conjugated, visualized with TMB
substrate and measured at 450 nm with 620 nm reference. Data was statistically evaluated with a
non-linear fit (sigmoidal four parameters logistic, X-axis is log).
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Table 24: EC50 (in µg/mL) of monoclonal scFv-Fc. EC50 was determined with a statistics software
using a non-linear fit (sigmoidal four parameter logistic, X-axis is log).
# Name antibody clone
DT
EC50
(µg/mL)
CRM197
EC50
(µg/mL)
#
Name 
antibody 
clone
DT
EC50
(µg/mL)
CRM197
EC50
(µg/mL)
1 ewe191-A7 0.0086 0.0108 31 ewe371-G2 0.02945 0.04119
2 ewe191-A9 0.0154 2.8240 32 ewe371-G4 0.2942 4.738
3 ewe191-C1 0.0101 0.0218 33 ewe371-G8 0.03405 0.04117
4 ewe191-C10 0.1748 1.5410 34 ewe371-H1 0.02254 0.06175
5 ewe191-C11 0.0105 0.0122 35 ewe371-H9 0.03138 0.04574
6 ewe191-C12 0.0254 0.0200 36 ewe372-A12 0.02153 0.03627
7 ewe191-D1 0.0100 0.0125 37 ewe372-A8 0.02257 0.02301
8 ewe191-E12 0.0459 0.0246 38 ewe372-C10-S 0.05643 0.2061
9 ewe191-H10 0.0335 0.0839 39 ewe372-C10-W 0.04717 0.1936
10 ewe191-H8 0.0143 0.0251 40 ewe372-C4 0.03015 0.03387
11 ewe192-A6 0.2031 0.6579 41 ewe372-C5 0.03221 0.03299
12 ewe192-B5(P) 0.0441 0.0587 42 ewe372-C8 0.03915 0.04011
13 ewe192-C11 0.0113 0.0227 43 ewe372-D11 0.02329 0.03616
14 ewe192-D7 0.0119 0.0133 44 ewe372-D12 0.04246 0.04771
15 ewe192-D8 3.9280 3.3680 45 ewe372-D3-S 0.05643 0.2061
16 ewe192-E4 0.0920 0.2222 46 ewe372-D3-W 0.04717 0.1936
17 ewe192-F11 0.49 2.0760 47 ewe372-D7 0.03223 0.0365
18 ewe192-F6 0.1558 0.5040 48 ewe372-D9 0.08502 0.2127
19 ewe192-G12 0.89 1.4080 49 ewe372-F3 0.03983 0.05432
20 ewe192-H11 0.0143 0.1678 50 ewe372-F6 0.01995 0.0313
21 ewe192-H7 0.0138 0.0144 51 ewe372-G2 0.02719 0.03091
22 ewe192-H8 0.1589 0.3111 52 ewe372-H1-S 0.0382 0.1002
23 ewe371-A2 0.08299 0.1176 53 ewe372-H1-W 0.0364 0.09968
24 ewe371-A6 0.03316 0.04078 54 ewe374-C9 0.1311 2.049
25 ewe371-B12 0.01456 0.0141 55 ewe374-E6 0.3193 2.255
26 ewe371-D10 0.02058 0.02136 56 ewe374-F7 0.01272 0.01367
27 ewe371-D4 0.02356 0.02439 57 ewe375-B8 0.1135 0.2739
28 ewe371-D7 0.02815 0.03871 58 ewe375-D2 0.03781 18.38
29 ewe371-E4 0.03578 0.1132 59 ewe375-D4 0.04593 0.06574
30 ewe371-E7 0.02544 0.03123 60 ewe375-G7 11.9 3.429
61 ewe375-H4 0.03662 0.1174
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3.4.2 Neutralization in scFv-Fc format
After the validation of binding to diphtheria toxin, the neutralization was analyzed in a cell
based in vitro assay (figure 10 and 11).
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Figure  10: Cell based neutralization assay of scFv-Fc antibodies. Untreated Vero cells are
given as green dotted line. The threshold for neutralization is given as red dotted line (50 %
of untreated Vero cells). The antibody ewe192-B5(P) (green, open symbol and dotted line) is
considered as positive control. All antibodies shown were further analyzed. Mitochondrial
activity was measured with an MTT assay after 6 days at OD570nm.
3 Results
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Figure 11: Cell based neutralization assay of scFv-Fc antibodies. Untreated Vero cells are given
as  green  dotted  line.  The  threshold  for  neutralization  is  given  as  red  dotted  line  (50 % of
untreated Vero cells). The antibody JöJ58B9 (red, open symbols and dotted line) is considered
as negative control, the antibody ewe192-B5(P) (green, open symbol and dotted line) as positive
control.  Antibodies  represented  in  colored  symbols  were  further  analyzed,  antibodies
represented in gray symbols were disregarded in further analysis. Mitochondrial activity was
measured with an MTT assay after 6 days at OD570nm.
3 Results
Table 25: Minimal effective dose 50 % (MED50%) in nM for scFv-Fc antibodies.
# Name antibody clone
MED 50% 
(nM) #
Name antibody 
clone
MED 50% 
(nM)
1 ewe191-A7 18854.3 31 ewe371-G2 1.107
2 ewe191-A9 1266.1 32 ewe371-G4 0.622
3 ewe191-C1 2360.9 33 ewe371-G8 9.841
4 ewe191-C10 1821.7 34 ewe371-H1 24.007
5 ewe191-C11 7.6 35 ewe371-H9 1.419
6 ewe191-C12 7.3 36 ewe372-A12 8.032
7 ewe191-D1 36.9 37 ewe372-A8 0.05126
8 ewe191-E12 43.2 38 ewe372-C10-S 0.00483
9 ewe191-H10 65.4 39 ewe372-C10-W 0.00551
10 ewe191-H8 3.9 40 ewe372-C4 0.03261
11 ewe192-A6 500.8 41 ewe372-C5 0.01906
12 ewe192-B5(P) 0.075 42 ewe372-C8 0.140
13 ewe192-C11 313.8 43 ewe372-D11 2.231
14 ewe192-D7 26.4 44 ewe372-D12 0.723
15 ewe192-D8 4667.8 45 ewe372-D3-S 128.760
16 ewe192-E4 301.3 46 ewe372-D3-W 63.490
17 ewe192-F11 1312.7 47 ewe372-D7 0.01039
18 ewe192-F6 287.9 48 ewe372-D9 1.470
19 ewe192-G12 2911.9 49 ewe372-F3 0.00339
20 ewe192-H11 5506.8 50 ewe372-F6 2.011
21 ewe192-H7 18.8 51 ewe372-G2 2.236
22 ewe192-H8 303.6 52 ewe372-H1-S 0.00515
23 ewe371-A2 77.27 53 ewe372-H1-W 0.00508
24 ewe371-A6 20.32 54 ewe374-C9 4.238
25 ewe371-B12 1.407 55 ewe374-E6 7.6778
26 ewe371-D10 5.496 56 ewe374-F7 7.641
27 ewe371-D4 0.642 57 ewe375-B8 0.946
28 ewe371-D7 10.621 58 ewe375-D2 151.617
29 ewe371-E4 16.373 59 ewe375-D4 0.00619
30 ewe371-E7 10.134 60 ewe375-G7 20.02
61 ewe375-H4 0.114
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The neutralization of the purified scFv-Fc was between 18.8 µM and 3.3 pM at a constant
amount of DT (4x MCD). For better visualization, antibodies with the lowest MED50% are
marked in yellow, antibodies with the highest MED50% are marked in gray (table 25).
It was shown, that all purified scFv-Fc antibodies have neutralizing potency against DT.
Most of the scFv-Fc had a neutralization efficacy in the nanomolar range.
3.4.3 Domain mapping
The  diphtheria  toxin  is  an  AB-toxin.  It  consists  of  2  fragments  (A-fragment  and  B-
fragment). The A-fragment is the catalytic part (= C-domain) and the B-fragment is divided
into 2 domains, the receptor binding domain (R-domain) and the translocation domain (T-
domain).  Each  fragment  and  domain  was  genetically  His-tagged  and  expressed  and
purified from E. coli. The purity and integrity of all recombinant protein was controlled by
SDS-PAGE followed by Coomassie blue staining (supplemental figure 31).
The recombinant proteins were separated by SDS-PAGE followed by immuno staining to
determine which domain of diphtheria toxin was recognized by each scFv-Fc (figure  12,
supplemental figure 32, 33 and 34).
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Figure  12:  Western Blot and immuno stain after SDS-PAGE for domain mapping of scFv-Fc
antibodies derived from panning with immobilized antigen. All scFv-Fc antibodies were tested
on both fragments of diphtheria toxin: A) A-fragment (21 kDa) and B) B-fragment (37 kDa).
Detected with goat α-human Fc antibody AP conjugated, visualized with NBT/BCIP. Antibodies
showed different binding patterns, i.e. either to the A or the B fragment of DT. JöJ58B9 served
as negative control.
A B
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Each  scFv-Fc  antibody  bound  specifically  to  one  of  the  two  fragments.  Here,  the
antibodies ewe192-C11, ewe192-D7, ewe192-H7 and ewe192-H11 bound specifically to
the  A-fragment.  The  antibodies  ewe192-A6,  ewe192-E4,  ewe192-F6,  ewe192-H8  and
ewe192-B5(P) bound specifically to the B-fragment. In case of B-fragment recognition, the
antibodies were further tested on the R- and T-domain. The antibody ewe192-B5(P) bound
to the R-domain, the other antibodies bound only the B-fragment (supplemental figure 34).
The antibodies ewe192-D8, ewe192-F11 and ewe192-G12 did not bind in Western blot at
all. Table 26 summarizes all scFv-Fc antibodies and which domain of the diphtheria toxin
they recognize.
Table 26: Analyzed scFv-Fc antibodies and their respective binding domain. nd = not determined
# Name antibody clone Domain #
Name antibody 
clone Domain
1 ewe191-A7 C-domain 31 ewe371-G2 R-domain
2 ewe191-A9 C-domain 32 ewe371-G4 nd
3 ewe191-C1 C-domain 33 ewe371-G8 R-domain
4 ewe191-C10 nd 34 ewe371-H1 nd
5 ewe191-C11 C-domain 35 ewe371-H9 R-domain
6 ewe191-C12 R-domain 36 ewe372-A12 C-domain
7 ewe191-D1 C-domain 37 ewe372-A8 R-domain
8 ewe191-E12 R-domain 38 ewe372-C10-S R-domain
9 ewe191-H10 C-domain 39 ewe372-C10-W R-domain
10 ewe191-H8 C-domain 40 ewe372-C4 R-domain
11 ewe192-A6 B-fragment 41 ewe372-C5 R-domain
12 ewe192-B5(P) R-domain 42 ewe372-C8 R-domain
13 ewe192-C11 C-domain 43 ewe372-D11 C-domain
14 ewe192-D7 C-domain 44 ewe372-D12 R-domain
15 ewe192-D8 nd 45 ewe372-D3-S nd
16 ewe192-E4 B-fragment 46 ewe372-D3-W nd
17 ewe192-F11 nd 47 ewe372-D7 R-domain
18 ewe192-F6 B-fragment 48 ewe372-D9 B-fragment
19 ewe192-G12 nd 49 ewe372-F3 R-domain
20 ewe192-H11 C-domain 50 ewe372-F6 T-domain
21 ewe192-H7 C-domain 51 ewe372-G2 R-domain
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# Name antibody clone Domain #
Name antibody 
clone Domain
22 ewe192-H8 B-fragment 52 ewe372-H1-S R-domain
23 ewe371-A2 nd 53 ewe372-H1-W R-domain
24 ewe371-A6 B-fragment 54 ewe374-C9 nd
25 ewe371-B12 C-domain 55 ewe374-E6 nd
26 ewe371-D10 R-domain 56 ewe374-F7 C-domain
27 ewe371-D4 R-domain 57 ewe375-B8 nd
28 ewe371-D7 B-fragment 58 ewe375-D2 nd
29 ewe371-E4 nd 59 ewe375-D4 R-domain
30 ewe371-E7 nd 60 ewe375-G7 B-fragment
61 ewe375-H4 C-domain
It  was shown, that  eight  scFv-Fc antibodies  bound specifically  the B-fragment  and 16
bound  the  C-domain  (=  A-fragment).  21  scFv-Fc  antibodies  bound  specifically  the
R-domain and one bound the T-domain. The domain of the other 15 scFv-Fc could not be
determined.
3.4.4 Epitope mapping of ewe192-B5
The  scFv-Fc  antibody  ewe192-B5(P)  was  the  first  neutralizer  developed  with  a
neutralization  potency  over  100  IU/mg.  This  antibody  recognizes  the  R-domain  of
diphtheria toxin. For determination of the epitope of this antibody a PepSpot membrane
with the sequence of the R-domain of diphtheria toxin was used (figure 13).
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Figure  13:  Epitope  mapping  for  ewe192-B5(P)  on  a  PepSpot
membrane  of  fragmented  R-domain  with  15  amino  acid  (aa)
spots and overlap of 12 aa. Detection of ewe192-B5(P) with goat
α-human HRP conjugated secondary antibody.
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The first 2 spots on the membrane were stained by the ewe192-B5(P) scFv-Fc antibody.
This  corresponds  to  the  amino  acids  AYSPGHKTQPFLHDG  (first  spot)  and
PGHKTQPFLHDGYAV  (second  spot).  The  overlapping  sequence  is  underlined
AYSPGHKTQPFLHDGYAV and gives the potential epitope. Figure 14 shows the epitope
(purple) in the structure of the full diphtheria toxin (shown in pdb-file 1DDT).
3.5 Characterization of monoclonal antibodies in IgG
The  best  neutralizing  scFv-Fc  antibodies  were  converted  into  IgG  format.  Therefor,
additional restriction sites were added on the VH and VL 5’ and 3’ end to fit into the IgG
vectors  pCSE1c  for  VH  or  one  of  the  two  VL vectors  pCSL3l  or  pCSL3k.  The  38
antibodies were produced for 7 days in EXPI293F cells, afterwards purified with protein A
and buffered  in  PBS.  Three  of  the  IgG antibodies  were not  producible  in  IgG format
(ewe372-C10-S, ewe372-F3 and ewe374-F7).
3.5.1 Binding on diphtheria toxin and CRM197 in IgG
After converting antibodies in the IgG format, the ability of the IgG antibodies to bind
diphtheria toxin and CRM197 was tested (figure 15).
59
Figure  14:  Protein  structure  of
diphtheria  toxin  (in  pdb-file  1DDT).
With the 3  domains  C-domain  (red),
T-domain  (blue)  and  R-domain
(green).  The  epitope  detected  with
PepSpot membrane is marked purple.
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Table 27: EC50 (in µg/mL) of monoclonal IgG.
# Name antibody 
clone
DT EC50 
(µg/mL) 
CRM197 EC50
(µg/mL)
1 ewe191-A7 0.0244 0.0245
2 ewe191-A9 0.0264 1.4110
3 ewe191-C1 0.0381 0.0311
4 ewe191-C10 0.3541 1.0200
5 ewe191-C11 0.0253 0.0312
6 ewe191-C12 0.0466 0.0468
7 ewe191-D1 0.0266 0.0310
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Figure 15: Titration ELISA of scFv-Fc antibodies for binding to diphtheria toxin (filled symbol,
solid line) and CRM197 (non-toxic mutant; open symbol, dotted line) with BSA as negative
control (line). Detected with goat α-human Fc HRP conjugated antibody, visualized with TMB
substrate and measured at 450 nm with 620 nm reference. Data was statistically evaluated with
a non-linear fit (sigmoidal four parameters logistic, X-axis is log).
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# Name antibody 
clone
DT EC50 
(µg/mL) 
CRM197 EC50
(µg/mL)
8 ewe191-E12 0.0297 0.0329
9 ewe191-H8 0.0285 0.0332
10 ewe191-H10 0.0578 0.0931
11 ewe192-A6 0.4095 40.0800
12 ewe192-B5(P) 0.0535 0.0679
13 ewe192-C11 0.0337 0.0312
14 ewe192-D7 0.0333 0.0291
15 ewe192-D8 0.3612 2.4640
16 ewe192-E4 0.0681 30.9200
17 ewe192-F6 0.1380 7.5480
18 ewe192-F11 0.2021 31.6400
19 ewe192-G12 0.5226 34.1600
20 ewe192-H7 0.0349 0.0245
21 ewe192-H8 0.0938 3.5430
22 ewe192-H11 0.0263 0.0453
23 ewe371-B12 0.0182 0.0214
24 ewe372-A12 0.0210 0.0291
25 ewe372-A8 0.0239 0.0279
26 ewe372-C10-W 0.0356 0.0548
27 ewe372-C4 0.0323 0.0381
28 ewe372-C5 0.0344 0.0398
29 ewe372-D11 0.0243 0.0311
30 ewe372-D7 0.0286 0.0329
31 ewe372-F6 0.0264 0.0284
32 ewe372-H1-S 0.0282 0.0467
33 ewe372-H1-W 0.0283 0.0416
34 ewe375-D4 0.0274 0.0362
35 ewe375-H4 0.0220 0.0343
All IgG antibodies bound the diphtheria toxin. Not all antibodies showed a proper binding
to the non-toxic mutant CRM197. EC50 for diphtheria toxin ranged from 0.0182 µg/mL to
0.523 µg/mL.  The  non-toxic  mutant  CRM197  showed  binding  in  the  range  of
0.0214 µg/mL to 40.08 µg/mL. For better visualization, antibodies with the lowest EC50
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are marked in yellow, antibodies with the highest EC50 are marked in gray (table 27).
Out  of  35  scFv-Fc  antibodies,  15  showed  a  more  than  3-fold  increased  binding  to
diphtheria toxin than to the similarly folded non-toxic DT-mutant CRM197. None of the
antibodies showed unspecific binding to BSA. All antibodies were further tested for their
neutralization potency.
3.5.2 Neutralization in IgG format
All the IgG were tested for their ability to neutralize the diphtheria toxin in a cell-based
neutralization assay (figure 16).
Nearly all produced IgG antibodies kept their neutralization abilities while changing the
format from scFv-Fc to IgG. One IgG lost its neutralization behavior, ewe191-C10. The
minimal  effective  dose  50 % of  all  purified  IgG antibodies  was  between  1.4  µM and
3.0 pM at a constant amount of DT (4x MCD). For better visualization, antibodies with the
lowest MED50% are marked in yellow, antibodies with the highest MED50% are marked
in gray (table 28).
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Figure 16: Cell-based neutralization assay of IgG antibodies. Untreated Vero cells are given as
green dotted line. The threshold for neutralization is given as red dotted line (50 % of untreated
Vero cells). Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
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Table 28: Minimal effective dose 50 % (MED50) for IgG antibodies.
# Name antibody 
clone
Minimal effective 
dose 50% (nM) 
1 ewe191-A7 140.3
2 ewe191-A9 1098.5
3 ewe191-C1 818.5
4 ewe191-C10 -
5 ewe191-C11 0.6
6 ewe191-C12 2.4
7 ewe191-D1 31.2
8 ewe191-E12 19.2
9 ewe191-H8 1.0
10 ewe191-H10 119.1
11 ewe192-A6 780.7
12 ewe192-B5(P) 0.007
13 ewe192-C11 116.7
14 ewe192-D7 3.4
15 ewe192-D8 949.3
16 ewe192-E4 35.7
17 ewe192-F6 357.6
18 ewe192-F11 1415.9
19 ewe192-G12 180.8
20 ewe192-H7 10.9
21 ewe192-H8 254.0
22 ewe192-H11 1351.3
23 ewe371-B12 1.2028
24 ewe372-A12 4.1944
25 ewe372-A8 0.0826
26 ewe372-C10-W 0.0057
27 ewe372-C4 0.0297
28 ewe372-C5 0.0133
29 ewe372-D11 1.6808
30 ewe372-D7 0.0062
31 ewe372-F6 0.6098
32 ewe372-H1-S 0.0057
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# Name antibody 
clone
Minimal effective 
dose 50% (nM) 
33 ewe372-H1-W 0.0030
34 ewe375-D4 0.0031
35 ewe375-H4 0.0669
The  MED50 % was  converted  in  International  Unit  (IU)  per  mg  by  using  the  WHO
International Standard for DT. The results are summarized in figure 17.
The monoclonal antibodies showed neutralization between 0 – 455 IU/mg. Rat hybridoma
antibodies  from  NIBSC  showed  neutralization  around  50  IU/mg  with  the  hybridoma
antibody  (gray)  and  the  recombinant  version  of  DT05  (rDT05;  light  gray).  Equine
Diphtheria Anti Toxin (DAT) is the currently common used therapeutic against diphtheria.
This polyclonal equine serum showed a neutralization of approximately 50 IU/mg (black).
The best neutralizing mAbs showed binding against the receptor binding domain. Binders
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Figure 17: Neutralization potency (IU/mg) of a Vero cell based neutralization assay. All measured
IgGs are given in the colors of their corresponding binding domain (red = C-domain, green = R-
domain,  blue  =  T-domain,  green/blue-striped  =  B-fragment,  yellow =  unknown domain).  All
striped or dotted bars belongs to the IgG derived from panning on microtiter plates, all full colored
bars  are  IgGs  derived  from  panning  in  solution.  The  gray  colored  antibodies  are  the  best
neutralizing antibodies from NIBSC, DT05 = rat hybridoma and rDT05 = recombinat IgG from
DT05. Black colored is the equine Diphtheria Anti Toxin (DAT) serum.
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derived  from  panning  in  solution  (full  colored  bars)  showed  on  average  a  better
neutralization potency than antibodies derived from panning on microtiter plates (dotted or
striped  bars).  The  best  neutralizing  antibody  against  the  receptor  binding  domain  is
ewe375-D4,  the  best  neutralizer  against  the  catalytic  domain  is  ewe375-H4  and  the
neutralizer against the T-domain is ewe372-F6. The next step was to test the combinations
of antibodies against different domains.
3.5.3 Synergistic effect (combination of antibodies)
Combinations of the antibodies determined with the best neutralization were used to mimic
a polyclonal serum and to detect potential synergistic effects. A cell-based neutralization
assay was performed combining antibodies. Three different approaches were performed.
First, all antibodies from either panning with immobilized antigen or panning in solution
were combined.  Second, all  antibodies recognizing the C-domain were combined.  And
third,  all  antibodies  recognizing  the  R-domain  were  combined  (figure  18).  For  the
antibodies derived from the panning in solution, combinations with antibodies against the
T-domain were also performed.
It was shown, when combining antibodies, the neutralization performance adjusts to the
best neutralizing antibody in the mixture. For the panning with immobilized antigen (figure
18 A) the antibody ewe192-B5(P) was the best neutralizing antibody and determined the
effect  in  the  mixture.  For  antibodies  from  the  panning  in  solution  (figure  18 B)  the
antibody ewe375-D4 was the best neutralizing antibody. Combining all antibodies together
did not show a synergistic effect.
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Figure 18: Cell-based neutralization assay of IgG antibody combinations. Untreated Vero cells are
given as green dotted line. The threshold for neutralization is given as red dotted line (50  % of
untreated Vero cells).  Combinations of antibodies are given in the following colors with filled
symbols and solid lines: All monoclonal antibodies (mAb) combined in brown, all mAbs against C-
domain in pink, mAbs against R-domain combined with mAbs against C-domain in yellow, mAbs
against  R-domain in  green,  mAbs against  R-domain combined with mAb against  T-domain in
turquoise and mAbs against C-domain combined with mAb against T-domain in purple. Negative
control was an unrelated antibody (TM43-E10; red circle with dotted line), positive control was the
best  neutralizing mAb alone A) ewe192-B5(P) B) ewe375-D4; green open symbol with dotted
line). Mitochondrial activity was measured with the MTT assay after 6 days at OD570nm.
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For  the  antibodies  derived  from  panning  in  solution,  a  more  detailed  analysis  of
combination was done. The best five neutralizing IgG antibodies were further tested in
each possible combination with the best neutralizers against the C-domain and the one
neutralizer  against  the  T-domain (supplemental  figure  35). An example  of  the  best  R-
domain neutralizer (ewe375-D4),  combined with the best T- and C-domain neutralizers
(ewe372-F6 and ewe375-H4, respectively) is shown in figure 19.
It  was  shown  that  the  neutralization  potency  of  the  best  neutralizer  in  the  mixture
determined the neutralization potency of all combinations. This was in all studied cases the
R-domain binder, here ewe175-D4. No additive or synergistic effect was observed while
analyzing combinations of monoclonal antibodies in vitro.
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Figure 19: Cell-based neutralization assay of IgG antibody combinations. Untreated Vero cells are
given as green dotted line. The threshold for neutralization is given as red dotted line (50 % of
untreated  Vero cells).  Single  antibodies  are  given in  a  single  color  (filled  symbol,  solid  line),
combinations of antibodies are given in the colors they domain is binding against (red = C-domain,
green = R-domain and blue = T-domain; filling of symbol and color of line variant). Mitochondrial
activity was measured with an MTT assay after 6 days at OD570nm.
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3.5.4 Antibody specificity test by immunoblot
All antibodies were tested for specificity. For that, a EXPI293F cell lysate was prepared
and separated on a SDS-PAGE followed by Western blot and immuno staining performed
with all IgG antibodies (figure 20, supplemental figure 36).
The specificity test showed that ewe191-C1 reacted unspecifically with the EXPI293F cell
lysate. All other samples showed no reaction and therefore, no unspecific reaction with the
cell lysate.
69
Figure 20: Specificity immuno blot. EXPI293F cell lysate blotted and stained
with  DT  neutralizing  IgG  antibodies.  Detection  with  goat  α-human  Fc
secondary antibody conjugated with AP and colored with AP substrate + NBT/
BCIP.
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3.5.5 Aggregation determination by SEC
An  analytic  size  exclusion  chromatography  (SEC)  was  used  to  determine  different
aggregation behavior of the best R-domain neutralizing IgG antibodies (figure 21).
The five analyzed IgG antibodies showed a peak for the monomer IgG (86 – 98.5 % area)
between 12.1 – 12.4 min (149 – 170 kDa) and a second peak for the dimers IgG (1.4 –
13.7 % area) between 10.1 – 10.5 min (328 – 394 kDa). The IgG antibody ewe372-C10-W
showed additionally a shoulder in front of the dimer peak. None of the IgG antibodies
showed an additional peak indicating aggregation.
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Figure  21:  Size  exclusion  chromatography  of  the  best  five  R-
domain neutralizing IgG antibodies. Superdex200 increase 10/300
GL column was used with a flow rate of 0.5 mL/min. An amount of
150 µg IgG was separated in 50 mM sodium phosphate buffer (pH
7.0). Shown is the absorption at 280 nm (mAU) in correlation to the
retention volume (mL).
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Diphtheria is a disease caused by toxigenic strains of Corynebacterium spp. that produce
diphtheria toxin (DT). The disease can be controlled by immunization and is therefore rare
in countries with sufficient immunization coverage. However, diphtheria is a significant
health problem in countries with poor immunization coverage or disrupted immunization
programs (Both et al. 2014).
In 2017, the WHO reported 8819 diphtheria cases worldwide, 35 of those in Europe. That
was the highest number since 2004  (“WHO World Health Organization: Immunization,
Vaccines  And  Biologicals.  Vaccine  Preventable  Diseases  Vaccines  Monitoring  System
2018 Global Summary Reference Time Series: DIPHTHERIA” 2018). Current outbreaks
of  diphtheria  are  in  Venezuela,  Yemen and Bangladesh.  In  Venezuela,  2,170 suspected
cases were reported since 2016, of these 1,249 were confirmed. A total of 287 deaths were
reported. The cumulative case fatality rate among confirmed cases is 23 %  (“Venezuela
Diphtheria Case Tally Hits 800 in 2018” 2018). In Yemen, 1,584 suspected cases were
reported since 2016. A total of 85 deaths were reported. The cumulative case fatality rate is
5.4 %. Children (<5 years of age) represent 20 % of suspected diphtheria cases and 38 %
of associated deaths (“Yemen Diphtheria and Cholera Update” 2018). In Bangladesh, 3,954
suspected  cases  were  reported  between  November  and  December  2017.  A total  of  31
deaths  were  reported  (“Cox’s  Bazar:  475,000  Rohingya  Children  Being  Vaccinated  as
Diphtheria Tally Rises” 2018).
In Europe,  there were 2 fatal cases of infected children,  2016 in Belgium and 2015 in
Spain.  These children died because the life-saving diphtheria anti-toxin (DAT) was not
available  in  Europe.  Already in 2014 it  was reported that  several  EU countries  posted
information that they have problems in re-stocking their current DAT supplies (Both et al.
2014). In 2017 a market survey showed that the Western world is running out of the only
medicine against the toxin itself. The main producers for DAT are located in India and
Russia  (“Diphtheria Antitoxin (DAT) Serum” 2017).  Beside the scarce supply of DAT,
there are other obvious disadvantages. First, it is an animal product and can cause serum
sickness,  an  immune  response  to  proteins  in  the  antiserum.  Second,  batch-dependent
variation between DAT production from different animals occur. Third, the stability and
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shelf-life  of  serum,  especially  in  the  regions  where  it  is  needed  the  most  is  a  severe
problem. And fourth, the production in horses is not complying with the animal welfare
rules.
4.1 Antibody development
In this  study, two different types of libraries were used. The naive libraries HAL9 and
HAL10 (Kügler et al. 2015) and two different immune libraries (VJN and CD138+ library)
were generated from the blood of diphtheria toxin boost-vaccinated volunteers.
Naive  antibody  gene  libraries  are  IgM based  and  contain  a  huge  variation  of  V-gene
families  and  because  of  random combinations  of  VH-  and  VL-genes  the  diversity  of
antibodies  is  increased.  Theoretically,  an antibody against  almost  every antigen can be
selected with this library type (Schwimmer et al. 2013).  The naive human antibody gene
library HAL9 and HAL10 used in  this  study have  a  diversity  of  1.5 •  1010 individual
antibody clones for HAL9 and 5 • 109 for HAL10 (Kügler et al. 2015).
It was expected that antibodies from the naive library against diphtheria toxin could be
selected because the library should theoretically contain antibodies against every possible
antigen. Twenty nine unique antibodies were found binding diphtheria toxin but non of
these antibodies showed the ability to neutralize diphtheria toxins in a cell-based in vitro
assay. The reason could be the epitope or the affinity of the selected antibodies. These
antibodies may not bind to neutralizing epitopes.  If  the affinity is  too low, an  in  vitro
affinity maturation could improve the naive library derived antibodies in neutralization
ability. Because of the huge number of antibodies derived from the panning with immune
libraries this approach was not pursued any further.
Compared  to  naive  libraries,  immune  libraries  have  the  advantage  of  higher-affinity
antibodies,  because these are already affinity matured  in vivo  (Wild et  al.  2003). After
vaccination,  B cells  are  stimulated to  produce pathogen-specific antibodies.  During the
first  vaccination in childhood, the plasma cells produce low affinity antibodies (mainly
IgM). After first contact with the antigen several rounds of hypermutation occurs followed
by  selection  of  B  cells  in  the  germinal  center  for  improved  antigen  binding.  These
improved B cells can differentiate to memory B cells and persist in spleen or nodes. During
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a  boost  vaccination  these  persisting  memory  B  cells  can  readily  proliferate  and
differentiate into plasma cells secreting a large amount of high-affinity antibodies (Siegrist,
Claire-Anne 2013). The plasma cells can be identified by their specific surface marker
CD138 which is not expressed by T or B cells (Lin et al. 2004).
The VJN library used all peripheral blood mononuclear cells (PBMC), the CD138+ library
used the genetic information of antibodies directly coming from matured B lymphocytes,
i.e. the antibody producing plasma cells. In this study, CD138 was used to select plasma
cells from the whole PBMCs. Normally, plasma cells are rarely found in the circulating
blood (2/ µL blood which corresponds to approximately 0.02 %) (Caraux et al. 2010). That
was  confirmed  during  selection  process  with  only  2,501  CD138  positive  cells  out  of
88,000,000 total cells (0.003 %). Here, additionally the instability of the surface marker
could have decreased the number of CD138+ total cell count. It is known that CD138 can
degrade in cold temperatures or when sample processing is delayed (Lin et al. 2004). With
the selected CD138+ cells a library with a diversity of 4.0 • 108 cfu/mL for the lambda light
chain library and 3.7 • 108 cfu/mL for the kappa light chain library was built. The total
PBMC libraries (VJN) had a diversity between 1.3 – 3.45 • 108 cfu/mL. Even though the
diversity of the immune libraries were lower compared to the naive libraries, they contain
more antibodies against the antigen used for immunization (Moon et al. 2011).
It was shown that immune libraries had much more benefit on the outcome of neutralizing
antibodies in both panning strategies. This was according to the expectations since IgG
antibodies  from  boost-vaccinated  volunteers  were  already  affinity  matured  in  vivo to
neutralizing antibodies.  In  this  study,  290 unique,  neutralizing antibodies  derived from
immune  libraries  were  selected.  When  targeting  an  antigen  that  was  already  used  for
immunization, it is preferred to use an immune library because the antibodies are naturally
pre-selected and matured against the antigen.
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Table 29: Summary of all selected antibodies separated by library type, light chain type, panning 
strategy, screening strategy and further characterization.
Library type Light chain type Screening strategy selected Ab
Naive (HAL 9/ HAL 10) Lambda+Kappa (mix) MTP scFv binding 39/92 29/39 29/29 0/29 - - -
Immune Lambda+Kappa (mix) MTP scFv binding 67/92 51/67 35/51 10/35 9/10 9/9 9/9
Lambda+Kappa (mix) MTP scFv binding 65/92 50/65 38/50 12/38 12/12 12/12 12/12
Immune Lambda in solution scFv-Fc neutralization 71/96 13/71 13/13 13/13 1/13 1/1 1/1
Immune Kappa in solution scFv-Fc neutralization 66/96 18/66 18/18 18/18 10/18 10/10 10/10
Lambda in solution scFv-Fc neutralization 54/96 3/54 3/3 3/3 0/3 - -
Kappa in solution scFv-Fc neutralization 77/96 5/77 5/5 5/5 2/5 2/2 2/2
Panning 
strategy
Produced & 
purified as 
scFv-Fc
Binding in 
ELISA as 
scFv-Fc
Neutralizing 
as scFv-Fc
Produced & 
purified as 
IgG
Binding in 
ELISA as 
IgG
Neutralizing 
as IgG
Immune (CD138+ selected)
Immune (CD138+ selected)
Immune (CD138+ selected)
4 Discussion
Moreover,  two different  panning strategies (figure  22) were used additional to  the two
library types: first, panning on microtiter plate (MTP) with immobilized antigen in a well
and using naive and immune libraries, and second, panning in solution with biotinylated
antigen, using only immune libraries (table 29).
Using panning on MTP, only 22 out  of  184 antibodies  derived from immune libraries
(12 %)  showed neutralization  after  a  selection  strategy  based on binding  to  diphtheria
toxin.  In  comparison,  with  the  panning  in  solution  strategy  268  out  of  384  (70 %)
neutralizing antibodies were selected.
During immobilization of the antigen on an MTP unspecific absorption to the well surface
led to undirected binding of the antigen in different orientations and partial denaturation on
the surface. Proteins bind in polystyrene surfaces because of their hydrophobic interaction
(Pyun  et  al.  1997).  That  leads  to  an  unnatural  folding  of  antigens  to  the  surface  and
therefrom binders against discontinuous epitopes are enriched (Schütte et al. 2009; Mansur
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Figure 22: Graphical comparison of the
two  panning  strategies:  Panning  on
microtiter plate (MTP) and Panning in
solution.
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et al. 2005). A disadvantage of the panning on MTP could be that due to the bound and
partially  denatured  antigen,  not  every epitope  is  potentially  accessible.  Probably,  some
epitopes  were  covered  by  overlapping  parts  of  the  protein  next  to  it  or  denaturation
damaged epitopes.
To circumvent this disadvantages of immobilized proteins, biotinylated proteins were used
with the panning in solution strategy. Therefore, the antigens were not bound on a surface
thus  kept  in  their  natural  folding.  The  antibodies  were  selected  via  pull  down  with
magnetic beads coupled to streptavidin. But also this strategy has its disadvantages. The
biotinylation is a non-directional reaction, that may lead to potential epitopes. With the
used  biotinylation  protocol  up  to  three  biotins  were  added  to  one  diphtheria  toxin.
Comparing the phage ELISA experiment on biotinylated and not-biotinylated diphtheria
toxin it was shown that biotinylation had no effect on the binding ability of the antibodies
coming from the panning in solution strategy.
But the panning strategy itself was not the only difference between the selection strategies,
the screening strategy changed with the panning strategy. When using panning on MTP, the
monoclonal scFv antibodies were screened for their ability to bind to diphtheria toxin in a
binding ELISA. The antibodies coming from panning in solution were directly sub-cloned
into scFv-Fc format and screened for their capability to neutralize diphtheria toxin in a
cell-based  in  vitro assay.  The  latter  strategy  could  lead  to  better  results,  because  the
production of scFv fragments in E. coli is omitted. E. coli can solely fold proteins correctly
in the periplasm due to the oxidizing environment that permits disulfide bond formation.
But the periplasm only account for approximately 8 – 16 % of the cell volume (Gaciarz et
al. 2016). The periplasm can easily overload or miss-folded antibodies can accumulate and
cause cell death that could result in a bias due to production quality and quantity. In order
to  avoid  that  a  production  in  mammalian  cells  was  performed.  The  benefit  of  the
production  immediately  in  mammalian  cells  was  that  the  monoclonal  antibodies  were
directly  screened for  their  ability  to  neutralize diphtheria  toxin in  a  cell-based  in  vitro
assay.
This study showed that the combination of using an immune library, panning in solution
and production as scFv-Fc in mammalian cells  with functional screening benefited the
discovery  of  DT  neutralizing  antibodies.  It  was,  however,  not  analyzed  whether  the
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combination of all strategies or one single component was most relevant for the outcome.
The only possible conclusion that can be made at this point is that the screening strategy
has to be specifically designed for the purpose of the desired antibodies. Here, the focus is
clearly on neutralization so the selection assay of choice was a functional assay testing
directly for neutralization in vitro.
4.2 Antibody format switching from scFv-Fc to IgG
After selecting neutralizing antibodies via panning, the characterization was further done in
IgG format. It was analyzed whether the previously characterized properties binding and
neutralization were effected after switching the antibody format from scFv-Fc to IgG.
For most of the generated antibodies from panning with immobilized antigen on MTP
affinity decreased after switching from scFv-Fc to IgG (14 out  of 22) (table  30).  This
reduced affinity was already described for another antibody (Thie et al. 2011). In scFv-Fc
format, the variable domains have a linker in between. This linker leads to an increased
flexibility of the variable domains compared to the IgG or Fab. The flexibility may result
in a changed angle between VH and VL that influence the binding ability  (Krebs et al.
2001; Thie et al. 2011).
This effect of decreased binding was mainly observed when binders were selected in the
MTP panning strategy, because here the selection criteria was the ability to bind DT. The
antibodies generated by panning in solution did not show this effect, but these antibodies
were already selected as scFv-Fc regarding their ability to neutralize diphtheria toxin. The
affinity remained the same or even increased for the panning in solution strategy while
binding to DT played a minor role (table 30).
Regarding the neutralization potency after format switching, nearly every antibody had an
increased ability to neutralize DT in a cell based in vitro assay (table  30). IgG increased
their potency compared to scFv-Fc up to 100-fold (ewe191-A7). Just one antibody lost the
ability to neutralize diphtheria toxin  in vitro (ewe191-C10). Switching the scFv format
back  to  the  original  Fab  format  increased  the  neutralization  efficacy.  On  average  the
potency  increased  7-fold.  This  effect  was  even  higher  in  the  antibodies  derived  from
panning on MTP. Here, the potency increase on average 10-fold.
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Table 30: Comparison of half effective concentration (EC50 in µg/mL) against diphtheria toxin and
minimum effective dose 50 % (MED50% in nM) against diphtheria toxin in the antibody formats
scFv-Fc and IgG. Antibodies developed with panning on microtiter plates are highlighted in gray,
those from panning in solution have a white background.
# Name antibody 
clone
DT EC50 
(µg/mL) scFv-Fc
DT EC50 
(µg/mL) IgG
MED50% 
(nM) scFv-Fc
MED50% 
(nM) IgG
1 ewe191-A7 0.0086 0.0244 18,854.3 140.3
2 ewe191-A9 0.0154 0.0264 1266.1 1098.5
3 ewe191-C1 0.0101 0.0381 2360.9 818.5
4 ewe191-C10 0.1748 0.3541 1821.7 -
5 ewe191-C11 0.0105 0.0253 7.6 0.6
6 ewe191-C12 0.0254 0.0466 7.3 2.4
7 ewe191-D1 0.0100 0.0266 36.9 31.2
8 ewe191-E12 0.0459 0.0297 43.2 19.2
9 ewe191-H10 0.0335 0.0285 65.4 119.1
10 ewe191-H8 0.0143 0.0578 3.9 1.0
11 ewe192-A6 0.2031 0.4095 500.8 780.7
12 ewe192-B5(P) 0.0441 0.0535 0.075 0.007
13 ewe192-C11 0.0113 0.0337 313.8 116.7
14 ewe192-D7 0.0119 0.0333 26.4 3.4
15 ewe192-D8 3.9280 0.3612 4667.8 949.3
16 ewe192-E4 0.0920 0.0681 301.3 35.7
17 ewe192-F11 0.49 0.2021 1312.7 1415.9
18 ewe192-F6 0.1558 0.1380 287.9 357.6
19 ewe192-G12 0.89 0.5226 2911.9 180.8
20 ewe192-H11 0.0143 0.0263 5506.8 1351.3
21 ewe192-H7 0.0138 0.0349 18.8 10.9
22 ewe192-H8 0.1589 0.0938 303.6 254.0
23 ewe371-B12 0.01456 0.0182 1.407 1.2028
24 ewe372-A12 0.02153 0.0210 8.032 4.1944
25 ewe372-A8 0.02257 0.0239 0.05126 0.0826
26 ewe372-C10-W 0.04717 0.0356 0.00551 0.0057
27 ewe372-C4 0.03015 0.0323 0.03261 0.0297
28 ewe372-C5 0.03221 0.0344 0.01906 0.0133
29 ewe372-D11 0.02329 0.0243 2.231 1.6808
30 ewe372-D7 0.03223 0.0286 0.01039 0.0062
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# Name antibody 
clone
DT EC50 
(µg/mL) scFv-Fc
DT EC50 
(µg/mL) IgG
MED50% 
(nM) scFv-Fc
MED50% 
(nM) IgG
31 ewe372-F6 0.01995 0.0264 2.011 0.6098
32 ewe372-H1-S 0.0382 0.0282 0.00515 0.0057
33 ewe372-H1-W 0.0364 0.0283 0.00508 0.0030
34 ewe375-D4 0.04593 0.0274 0.00619 0.0031
35 ewe375-H4 0.03662 0.0220 0.114 0.0669
4.3 Domain Mapping
The three domains  of  DT have different  functions  (Choe et  al.  1992). Therefore,  it  is
important  to  know which  domain  are  bound.  The  selected  neutralizing  antibodies  are
binding to all three DT domains. However, in this study just one neutralizing antibody
could  be  identified  that  targets  the  T-domain.  Most  of  the  antibodies  bind  to  the  C-
(16 mAbs) or R-domain (21 mAbs) (figure 23).
The best neutralizing antibodies have a neutralization potency of 3 – 30 pM, including the
neutralizing  antibody  ewe375-D4  (3  pM)  and  ewe192-B5(P)  (7  pM).  All  of  these
antibodies bind to the receptor binding domain and might physically block the toxin from
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Figure  23:  Overview  of  analyzed  monoclonal
antibodies  (mABs)  and  their  respective  binding
domain
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binding to the receptor,  the heparin-binding epidermal growth factor-like growth factor
(HB-EGF). Three other studies showed already that antibodies against the receptor binding
domain lead to effective neutralization (Sevigny et al. 2013; Kakita et al. 2006; Danelli et
al. 1991). The epitope for the R-domain binding antibody ewe192-B5(P) was mapped. It
was shown, that the epitope is at the N-terminus of the R-domain and therefore not directly
blocking the binding site (brown, figure 24). The antibody might inhibit the conformational
change of the T-domain,  because it  binds to the N-terminal part  of R-domain probably
proceeding  to  the  C-terminal  part  of  the  T-domain  (the  used  peptide  spot  membrane
included only the R-domain).
The antibody against the T-domain might prevent the DT from changing the conformation
to form the pore for endosomal escape. Here, steric hindrance may lead to neutralization
while binding the T-domain.
Binding the C-domain might have two different mechanism of neutralization.  The first
mode of action of neutralizing antibodies might be the blocking of the catalytic site. While
blocking the NAD-binding pocket the elongation factor 2 can not be ribosylated and thus
cells have a functional protein synthesis. Up to now it is not known in which way the
C-domain binding antibodies are neutralizing. But to cover more than just blocking the
receptor binding or to prevent the catalytic function, antibodies against different domains
were combined to mimic a polyclonal serum.
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Figure  24:  DT with  active site  in  C
domain (cyan)  and Receptor  binding
site (brown)
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4.4 No synergistic effect with antibody combinations in vitro
We hypothesized that a combination of neutralizing antibodies against different domains of
DT lead to an additive or synergistic effect. Some publications already reported that mixing
of protective monoclonal antibodies targeting different epitopes of a toxin can synergize
protective efficacy and thus an increase protection against toxicity, examples are given for
AB-toxins (Cheng et al. 2009; Ngundi et al. 2012; Brossier et al. 2004) and enterotoxins
(Demarest et al. 2010; Varshney et al. 2011).
In this study, cell-based neutralization assays were performed and no synergistic effects
were observed. Neutralization of the mixture was always as good as the best neutralizing
antibody by itself. In contrast to this in vitro study, previous studies were mainly conducted
in vivo. Positive effects that may be caused by the immune system of the  in vivo model
may be able to tip the scale in favor of a specific antibody or antibody mix. However, in an
in vitro assay characterization of antibodies is easier and can be done with a huger panel of
antibodies.
In an in vitro assay, only the variable part of an antibody can influence the mode of action
because  the  Fc-part  of  the  antibody  can  only  be  activated  together  with  the  immune
system.  It  was  already  observed,  that  Fcγ  receptor  (FcγR)  mediated  mechanisms  are
important for toxin protection. For example, the Fc-mediated uptake of anthrax, a toxin
secreted by B. anthracis that is eponymic to the disease, by effector cells like macrophages
contributes substantially to the neutralizing activity of anti-anthrax toxin mAbs (Abboud et
al.  2010; Chow et al.  2013). During my study, the cell-based  in vitro assay reached its
limits. Nonetheless, the assay was well suited to pre-select the best 35 candidates out of
nearly 300 human, DT-neutralizing, monoclonal antibodies generated in the study.
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4.5 Conclusion and Outlook
In this study, the antibody phage display technology was used to generate a broad panel of
fully human monoclonal antibodies that neutralize diphtheria toxin. These antibodies have
four  striking  advantages  over  commonly  used  antisera.  First,  these  new  developed
antibodies are fully human. Second, they are a defined product with known sequences.
Third, they are a stable product, that can be lyophilized and stored over long periods of
time (data not shown). And finally, the antibodies can be produced in cell culture avoiding
the need for animals.
In this study, 660 monoclonal antibodies were selected. They were analyzed for binding
and neutralization in scFv-Fc and IgG format and 290 scFv-Fc antibodies have neutralizing
potency. All of these new developed antibodies derived from an immune library generated
with the blood of DT boost-vaccinated persons.  Three best neutralizing lead candidates
were selected, one against each of the three domains of DT. The IgG targeting the receptor
binding domain is ewe372-D4 and has a neutralization potency of 446 IU/mg. ewe375-H4
has a neutralization potency of 20.4 IU/mg and binds the catalytic domain and ewe372-F6
binds the translocation domain with a neutralization potency of 2.25 IU/mg. These IgG
antibodies together with the well characterized, R-domain binding ewe192-B5(P) antibody
(124 IU/mg) will be further analyzed.
In the next step, the antibodies  ewe192-B5(P), ewe375-D4, ewe372-F6 and ewe375-H4
and antibody mixtures will be tested in a non-lethal  in vivo guinea pig model. This skin
irritation model should show how the antibodies will react in an in vivo system.
In addition, the epitopes of all good neutralizing antibodies should be mapped. This can
provide more information about  the epitopes  and possible  explanations for  the way of
neutralization.
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Table 31: Oligonucleotides used in this Study
Primer name Sequence Used for
MHLacZ-Pro_f GGCTCGTATGTTGTGTGG Colony PCR
MHgIII_r CTAAAGTTTTGTCGTCTTTCC Colony PCR
ToR-pCMV-mlgG01-
Fc-seq-f 
CACTTTGCCTTTCTCTCC Colony PCR
ToR-pCMV-mlgG01-
Fc-seq-r 
CAGATGGCTGGCAACTAG Colony PCR
CM2_f CGCAAATGGGCGGTAGGCGTG Sequencing
ToR-pCMV-Seq-f TGGTAGCAACAGCTACAG Sequencing
ewe_DT-C-Nhe_f GCGTGGCTAGCGGCGCTGATGATG DT cloning
ewe_DT-C-Not_r GCACGCGGCCGCTCGCCTGACACG DT cloning
ewe_DT-B-Nhe_f GCGTGGCTAGCTCAGTAGGTAGCTCATTGTC DT cloning
ewe_DT-T-Not_r GCACGCGGCCGCGGGACGATTATACGAATTATG DT cloning
ewe_DT-R-Nhe_f GCGTGGCTAGCGCGTATTCTCCGGG DT cloning
ewe_DT-B-Not_r GCACGCGGCCGCGCTTTTGATTTCAAAAAATAGCG DT cloning
EwC1+A6+E4+G12Ag
eI_f
AAAGCACCGGTGAAACGACACTCACGCAG IgG subcloning
EWE_VH-4-BssHII_f TGAGCGGCGCGCACTCCCAAATGCAGCTGGTGCAG IgG subcloning
EWE_VH-5-NheI_r TGAGCCGCTAGCTGCGGAGACGGTGACTGTG IgG subcloning
EWE_VH-6-NheI_r TGAGCCGCTAGCTGAGGAGATGGTGACCATTG IgG subcloning
EWE_VL-5_BsiWI_r TGAGCCCGTACGTCTAATCTCCAGCTTGGTCC IgG subcloning
EWE_VL-6_BsiWI_r TGAGCCCGTACGTCTGATTTCCACTTTGGTCC IgG subcloning
AF_pCSL3_DraIII-rev AGTGACACTTGGTGCAGCCTTGGGCTGACC IgG subcloning
AF120.2-
H2_LC_AgeI_f 
TGAGCCACCGGTGAAATTGTGTTGACGCAG IgG subcloning
AF165R4.2-G11-
HC_BssHII_f
CACAGGCGCGCACTCCGAGGTGCAGCTGGTGC IgG subcloning
AF311-G6-
VH_BssHII_f
CCACAGGCGCGCACTCCCAGCTGCAGCTGCAGGAG IgG subcloning
AF311-H7-
VH_BssHII_f
CCACAGGCGCGCACTCCCAGGTGCAGCTGGT IgG subcloning
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AF312-
G1VH_BssHII_f 
CCACAGGCGCGCACTCCCAGGTCCAGCTGGTGCAG IgG subcloning
ew191_2C1+B5_BsiW
I_r 
TGAGCCCGTACGTTTGATCTCCACCTTGGTCC IgG subcloning
Ew191-
C10_VL_AgeI_f 
AAAGCACCGGTCAGCCAGTGCTAACTCAG IgG subcloning
Ew191-
C12_VL_AgeI_f 
AAAGCACCGGTTCCTATGTGCTGACACAG IgG subcloning
Ew191/2-
A7+D8_AgeI_f
AAAGCACCGGTTCCTATGAGCTGACTCAG IgG subcloning
ew191/2C1+B5_BsiWI
_r 
TGAGCCCGTACGTTTGATCTCCACCTTGGTCC IgG subcloning
Ew191/2D1+F11_AgeI
_f 
AAAGCACCGGTCAGTCTGTGTTGACGCAG IgG subcloning
ew191E12_VL_DraIII_
r 
AGTGACACTTGGTGCGGCCTTGGGCTGACCTAG IgG subcloning
ew191F11_VL_DraIII_
r
AGTGACACTTGGTGCGGCCTTGGGCTGACTTAG IgG subcloning
Ew192-B5_VL_AgeI_f AAAGCACCGGTGCCATCCAGATGACCCAG IgG subcloning
Ew192-
C11_VL_AgeI_f
AAAGCACCGGTCAGGCTGTGGTGACTCAG IgG subcloning
Ew192-F6_VL_AgeI_f AAAGCACCGGTGAAGTTGTGCTGACACAG IgG subcloning
ew192-
G12_VL_BsiWI_r 
TGAGCCCGTACGTTTGATATCCACCTTGGTCC IgG subcloning
EwC1+A6+E4+G12Ag
eI_f
AAAGCACCGGTGAAACGACACTCACGCAG IgG subcloning
EWE_VH-1-BssHII_f TGAGCGGCGCGCACTCCCAGGTGCAGCTGCAACAG IgG subcloning
EWE_VH-1-NheI_r TGAGCCGCTAGCTGAAGAGACGGTGACCAG IgG subcloning
EWE_VH-2-BssHII_f TGAGCGGCGCGCACTCCCAGGTGCAGCTACAACAG IgG subcloning
EWE_VH-2-NheI_r TGAGCCGCTAGCGGAGGAGACGGTGACCAG IgG subcloning
EWE_VH-3-BssHII_f TGAGCGGCGCGCACTCCCAAGTGCAGCTGGTGCAATC IgG subcloning
EWE_VH-3-NheI_r TGAGCCGCTAGCTGAGGAGACAGCGACCAG IgG subcloning
EWE_VH-4-NheI_r TGAGCCGCTAGCGGAGGCTGAGGAGACGGTG IgG subcloning
EWE_VL-1-AgeI_f AAAGCACCGGTGACATCCGGATGACCCAG IgG subcloning
EWE_VL-1-BsiWI_r TGAGCCCGTACGTTTGACGTCTACCTTGGTCC IgG subcloning
EWE_VL-2-AgeI_f AAAGCACCGGTGCCATCCGGTTGACCCAG IgG subcloning
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EWE_VL-2-BsiWI_r TGAGCCCGTACGTTTGATGTCTACCTTGGTCC IgG subcloning
EWE_VL-3-AgeI_f AAAGCACCGGTGATGTTGTGCTGACTCAG IgG subcloning
EWE_VL-3-BsiWI_r TGAGCCCGTACGTTTGATATCCACTTTGGTCC IgG subcloning
EWE_VL-4-AgeI_f AAAGCACCGGTGAAATTGTGATGACACAG IgG subcloning
EWE_VL-4-BsiWI_r TGAGCCCGTACGCTTGATCTCTACCTTGGTCC IgG subcloning
EWE_VL-5-AgeI_f AAAGCACCGGTGACATCCAGATGACACAG IgG subcloning
Ewe-
B5P_VH_BssHIII_f
TGAGCGGCGCGCACTCCCAGGTGCAGCTGCAGCAG IgG subcloning
ewe191_1_IgG-VH_r TGAGCCGCTAGCTGAGGAGACGGTGACCAG IgG subcloning
ewe191-A9_IgG-VH_r TGAGCCGCTAGCTGAAGAGATGGTGACCATTG IgG subcloning
ewe191-
A9_VH_BssHIII_f
TGAGCGGCGCGCACTCCCAAGTCCAGCTGGTACAG IgG subcloning
ewe191-C1_IgG-VH_r TGAGCCGCTAGCTGAGGACACGGTGACCGTG IgG subcloning
ewe191A7_VL_DraIII
_r 
AGTGACACTTGGTGCAGCCTTGGGCTGACGTAG IgG subcloning
ewe191C/E12_IgG-
VH_r 
TGAGCCGCTAGCTGAGGAGACGGTGACCCG IgG subcloning
ewe191D1_VL_DraIII
_r 
AGTGACACTTGGTGCAGCCTTGGACTGACCTAG IgG subcloning
Ewe192_5_IgG-VH_r TGAGCCGCTAGCTGAGGAGACGGTGACTGTG IgG subcloning
Ewe192_7_IgG-VH_r TGAGCCGCTAGCTGAAGAGATGGTGACGATTG IgG subcloning
Ewe192_8_IgG-VH_r TGAGCCGCTAGCTGAGGAGATGGTGACCATTG IgG subcloning
ewe192-
A6+H8_BsiWI_r
TGAGCCCGTACGTTTAATCTCCAGTCGTGTCC IgG subcloning
ewe192-B5_IgG-VH_r TGAGCCGCTAGCTGAGGAGACAGTGACTAG IgG subcloning
ewe192-
B5_VH_BssHIII_f
TGAGCGGCGCGCACTCCCAGGTGCAGCTATAGCAG IgG subcloning
ewe192-
E4_VL_BsiWI_r 
TGAGCCCGTACGTCTGATCTCCACCTTGGTCC IgG subcloning
ewe192-
F6_VL_BsiWI_r 
TGAGCCCGTACGTTTGATTTCCACCTTGGTCC IgG subcloning
ewe192-
H7_VH_BssHIII_f 
TGAGCGGCGCGCACTCCGAAGTGCAGCTGGTGGAG IgG subcloning
JOZ_AgeI_JOZ376-
C5_f
GATCACCGGTGAAATTGTGCTGACTCAG IgG subcloning
95
 Supplemental Information
Primer name Sequence Used for
JOZ_AgeI_JOZ376E12
_f
AAAGCACCGGTGATATTGTGATGACTCAG IgG subcloning
MaK_9E10_VH_BssHI
I_f 
CACAGGCGCGCACTCCCAGGTGCAGCTGCAGGAG IgG subcloning
MHSH1684-C12-
BssHII_f 
GCGTGGCGCGCACTCCCAGGTTCAGCTGGTGCAG IgG subcloning
MZI15_A2_AgeI_F AAAGCACCGGTCAGTCTGTGCTGACGCAGCC IgG subcloning
MZI8_1.2_D11_AgeI_
F
AAAGCACCGGTCAGTCTGCCCTGACTCAGC IgG subcloning
MZI8_1.2_D11_BssHII
_F
CACAGGCGCGCACTCCCAGGTACAGCTGCAGCAGTC IgG subcloning
MZI8_1.4_D1_AgeI_F AAAGCACCGGTCAGGCTGTGCTGACTCAGC IgG subcloning
SH1785-E8_NheI_r TGAGCCGCTAGCTGAGGAGACAGTGACCAG IgG subcloning
SoS-AgeI-SH83-
A7VK-f 
CATAACCGGTGACATCCAGATGACCCAGT IgG subcloning
SoS-AgeI-SUW117-
H2VL-f
CAATACCGGTCAGTCTGTGCTGACTCAGCCA IgG subcloning
SoS-AgeI-SUW119-
H2VL-f 
GTACACCGGTCAGCCTGTGCTGACTCAGC IgG subcloning
SoS-BssHII-SUW57-
D11VH-f 
CAAGGCGCGCACTCCCAGGTGCAACTGCAGGAGTCG IgG subcloning
SUW_AgeI_313-B5_f CAGCACCGGTCTGCCTGTGCTGACTCAGCC IgG subcloning
SUW_BssHII_hMN-
14VH_f
CACAGGCGCGCACTCCGAGGTGCAGCTGGTGGAG IgG subcloning
MHVH1_f: CAG GTB CAG CTG GTG CAG TCT GG Library cloning
MHVH1/7_f: CAR RTS CAG CTG GTR CAR TCT GG Library cloning
MHVH2_f: CAG RTC ACC TTG AAG GAG TCT GG Library cloning
JokVH3_f1: SAG GTG CAG CTG GTG GAG TCT GG Library cloning
JokVH3_f2: GAR GTG CAG CTG KTG GAG TCT GG Library cloning
MHVH4_f1: CAG GTG CAR CTG CAG GAG TCG GG Library cloning
JokVH4_f2: CAG GTG CAG CTA CAR CAG TGG GG Library cloning
JokVH4_f2: CAG CTG CAG CTG CAG GAG TCS GG Library cloning
MHVH5_f: GAR GTG CAG CTG GTG CAG TCT GG Library cloning
MHVH6_f: CAG GTA CAG CTG CAG CAG TCA GG Library cloning
MHkappaCL_r: ACA CTC TCC CCT GTT GAA GCT CTT Library cloning
MHVL1_f1: CAG TCT GTG CTG ACT CAG CCA CC Library cloning
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MHVL1_f2: CAG TCT GTG YTG ACG CAG CCG CC Library cloning
MHVL2_f: CAG TCT GCC CTG ACT CAG CCT Library cloning
MHVL3_f1: TCC TAT GWG CTG ACW CAG CCA CC Library cloning
MHVL3_f2: TCT TCT GAG CTG ACT CAG GAC CC Library cloning
MHVL4_f1: CTG CCT GTG CTG ACT CAG CCC Library cloning
MHVL4_f2: CAG CYT GTG CTG ACT CAA TCR YC Library cloning
MHVL5_f: CAG SCT GTG CTG ACT CAG CC Library cloning
MHVL6_f: AAT TTT ATG CTG ACT CAG CCC CA Library cloning
MHVL7/8_f: CAG RCT GTG GTG ACY CAG GAG CC Library cloning
MHVL9/10_f: CAG SCW GKG CTG ACT CAG CCA CC Library cloning
MHlambdaCL_r: TGA ACA TTC TGT AGG GGC CAC TG Library cloning
MHVK1_f1: GAC ATC CAG ATG ACC CAG TCT CC Library cloning
MHVK1_f2: GMC ATC CRG WTG ACC CAG TCT CC Library cloning
MHVK2_f: GAT RTT GTG ATG ACY CAG WCT CC 3 Library cloning
MHVK3_f: GAA ATW GTG WTG ACR CAG TCT CC Library cloning
MHVK4_f: GAC ATC GTG ATG ACC CAG TCT CC Library cloning
MHVK5_f: GAA ACG ACA CTC ACG CAG TCT CC Library cloning
MHVK6_f: GAW RTT GTG MTG ACW CAG TCT CC Library cloning
MHkappaCL_r: ACA CTC TCC CCT GTT GAA GCT CTT Library cloning
Table 32: 130 scFv-Fc V gene information. Outcome of panning with immobilized a ntigen.
Antibody
clones
VH VL
V D J V J
ewe190-A11__f IGHV1-69*01 IGHD3-22*01 IGHJ3*02 IGLV6-57*01 IGLJ3*02
ewe190-A2__f IGHV3-30*18 IGHD1-26*01 IGHJ3*02 IGLV3-1*01 IGLJ1*01
ewe190-A3__f IGHV3-9*01 IGHD1-26*01 IGHJ4*02 IGLV6-57*01 IGLJ3*02
ewe190-A6__f IGHV4-4*02 IGHD1-26*01 IGHJ3*02 IGLV1-44*01 IGLJ3*02
ewe190-A9__f IGHV4-4*02 IGHD3-16*01 IGHJ3*02 IGLV1-50*01 IGLJ3*02
ewe190-B10__f IGHV3-30*18 IGHD3-3*01 IGHJ4*02 IGLV1-44*01 IGLJ1*01
ewe190-B1__f IGHV3-23*04 IGHD3-16*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
ewe190-C10__f IGHV3-23*04 IGHD3-22*01 IGHJ3*02 IGLV3-1*01 IGLJ3*01
ewe190-C11__f IGHV3-30*18 IGHD1-26*01 IGHJ4*02 IGLV3-21*01 IGLJ3*02
ewe190-C2__f IGHV1-46*03 IGHD3-22*01 IGHJ6*03 IGLV1-40*01 IGLJ3*02
ewe190-C5__f IGHV6-1*01 IGHD5-12*01inv IGHJ6*02 IGLV1-47*02 IGLJ3*02
ewe190-C6__f IGHV5-51*01 IGHD3-22*01 IGHJ3*02 IGLV1-44*01 IGLJ3*01
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Antibody
clones
VH VL
V D J V J
ewe190-D3__f IGHV1-24*01 IGHD1-26*01 IGHJ4*02 IGLV6-57*01 IGLJ3*02
ewe190-D6__f IGHV3-23*04 IGHD2-15*01inv IGHJ4*02 IGLV1-44*01 IGLJ3*01
ewe190-D7__f IGHV3-23*04 IGHD3-9*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
ewe190-D8__f IGHV4-4*02 IGHD3-10*01 IGHJ3*02 IGLV1-44*01 IGLJ1*01
ewe190-D9__f IGHV1-f*01 IGHD5-5*01 IGHJ4*02 IGLV3-19*01 IGLJ3*02
ewe190-E10__f IGHV3-9*01 IGHD3-3*02 IGHJ4*02 IGLV1-44*01 IGLJ1*01
ewe190-E1__f IGHV3-9*01 IGHD3-22*01 IGHJ4*02 IGLV2-8*01 IGLJ1*01
ewe190-E3__f IGHV3-30*18 IGHD4-17*01 IGHJ4*02 IGLV6-57*01 IGLJ3*02
ewe190-E5__f IGHV1-46*03 IGHD3-22*01 IGHJ6*03 IGLV1-40*01 IGLJ1*01
ewe190-E6__f IGHV1-18*01 IGHD1-26*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01
ewe190-G10__f IGHV3-23*04 IGHD5-12*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
ewe190-G11__f IGHV1-69*06 IGHD3-9*01 IGHJ3*02 IGLV1-47*01 IGLJ3*01
ewe190-G4__f IGHV1-69*01 IGHD6-19*01 IGHJ5*02 IGLV1-40*01 IGLJ3*01
ewe190-H11__f IGHV4-4*02 IGHD2-15*01inv IGHJ4*02 IGLV1-44*01 IGLJ1*01
ewe190-H1__f IGHV3-9*01 IGHD4-17*01 IGHJ6*02 IGLV3-19*01 IGLJ3*02
ewe190-E7__f IGHV1-46*03 IGHD3-22*01 IGHJ6*03 IGLV1-40*01 IGLJ3*02
ewe190-H10__f IGHV3-9*01 IGHD3-22*01 IGHJ4*02 IGLV2-8*01 IGLJ1*01
E09_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGLV1-44*01 IGLJ1*01
E10_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV1-16*02 IGKJ4*01
E11_4519__f IGHV1-3*01 IGHD6-19*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01
E12_4519__f IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
ewe191-G10__f IGHV1-f*01 IGHD4-23*01 IGHJ6*02 IGLV1-40*01 IGLJ1*01
ewe191-G11__f IGHV1-3*01 IGHD6-19*01 IGHJ4*02 IGLV1-40*01 IGLJ3*02
ewe191-G3__f IGHV1-18*01 IGHD2-21*02 IGHJ4*02 IGLV2-14*04 IGLJ3*02
ewe191-G4__f IGHV1-69*04 IGHD2-2*02inv IGHJ4*02 IGKV3-11*01 IGKJ4*01
ewe191-G5__f IGHV5-51*01 IGHD3-10*01 IGHJ5*02 IGLV8-61*01 IGLJ3*02
ewe191-G6__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
ewe191-G8__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV1D-39*01 IGKJ5*01
ewe191-G9__f IGHV1-18*01 IGHD2-21*02 IGHJ4*02 IGKV3-20*01 IGKJ3*01
ewe191-H10__f IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*02
ewe191-H11__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-14*01 IGLJ3*01
ewe191-H1__f IGHV1-69*06 IGHD2-15*01 IGHJ4*02 IGLV8-61*01 IGLJ3*02
ewe191-H8__f IGHV3-23*04 IGHD3-10*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
F01_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
F02_4519__f IGHV1-f*01 IGHD3-22*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02
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VH VL
V D J V J
F03_4519__f IGHV1-f*01 IGHD4-23*01 IGHJ6*02 IGLV3-19*01 IGLJ3*01
F04_4519__f IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*02
F05_4519__f IGHV1-69*01 IGHD3-22*01 IGHJ6*02 IGLV3-21*02 IGLJ3*01
F06_4519__f IGHV1-3*01 IGHD6-19*01 IGHJ4*02 IGLV2-8*01 IGLJ3*01
F08_4519__f IGHV3-21*01 IGHD3-3*02 IGHJ3*02 IGLV6-57*01 IGLJ3*01
F09_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
F10_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV3-15*01 IGKJ4*01
F12_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
G01_4519__f IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV6-57*01 IGLJ3*01
G02_4519__f IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV3-21*02 IGLJ3*01
G03_4519__f IGHV3-33*01 IGHD6-13*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01
G04_4519__f IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV1-44*01 IGLJ3*01
G05_4519__f IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGLV1-47*02 IGLJ3*01
G06_4519__f IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV3-19*01 IGLJ3*01
G07_4519__f IGHV4-4*02 IGHD4-17*01 IGHJ4*02 IGLV1-44*01 IGLJ7*01
G08_4519__f IGHV1-f*01 IGHD4-23*01 IGHJ6*02 IGLV3-1*01 IGLJ1*01
G09_4519__f IGHV1-3*02 IGHD2-2*01 IGHJ5*02 IGLV2-14*04 IGLJ1*01
G10_4519__f IGHV1-2*02 IGHD3-22*01 IGHJ6*02 IGLV1-44*01 IGLJ3*01
G11_4519__f IGHV4-34*01 IGHD1-1*01 IGHJ6*02 IGLV1-44*01 IGLJ3*02
G12_4519__f IGHV1-69*06 IGHD6-19*01 IGHJ6*02 IGKV2D-28*01
H02_4519__f IGHV5-51*01 IGHD3-10*02 IGHJ5*02 IGLV6-57*01 IGLJ3*01
H03_4519__f IGHV3-33*02 IGHD6-13*01 IGHJ4*03 IGLV1-47*01 IGLJ3*01
H04_4519__f IGHV5-51*01 IGHD3-16*01 IGHJ5*02 IGLV1-44*01 IGLJ1*01
H05_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV6-57*01 IGLJ3*01
H06_4519__f IGHV3-21*01 IGHD2-21*02 IGHJ4*02 IGKV3-20*01 IGKJ1*01
H07_4519__f IGHV1-69*04 IGHD4-17*01 IGHJ4*02 IGKV1D-39*01 IGKJ3*01
H08_4519__f IGHV1-3*01 IGHD6-19*01 IGHJ4*02 IGLV1-44*01 IGLJ1*01
H09_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-14*04 IGLJ1*01
H10_4519__f IGHV1-3*01 IGHD2-2*01 IGHJ6*02 IGLV3-21*02 IGLJ1*01
H11_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGLV1-44*01 IGLJ1*01
H12_4519__f IGHV3-21*01 IGHD2-15*01 IGHJ4*02 IGKV1D-39*01 IGKJ2*01
F07_4519__f IGHV1-3*01 IGHD6-19*01 IGHJ4*02 IGLV2-8*01 IGLJ3*01
H01_4519__f IGHV1-3*01 IGHD3-10*01 IGHJ6*02 IGKV1D-39*01 IGKJ5*01
A01_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGKV1D-39*01 IGKJ4*01
A02_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
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A03_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-40*01 IGLJ3*01
A04_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-8*01 IGLJ3*02
A05_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ5*01
A06_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ4*01
A07_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*02
A08_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-47*01 IGLJ3*02
A09_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*02
A10_4519__f IGHV4-34*01 IGHD4-17*01 IGHJ2*01 IGKV1D-39*01 IGKJ4*01
A11_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV1-40*01 IGLJ3*01
A12_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-8*01 IGLJ3*01
B01_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ5*01
B02_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-11*01 IGLJ3*02
B03_4519__f IGHV4-30-2*01 IGHD3-22*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01
B04_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV3-25*03 IGLJ3*01
B05_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-8*01 IGLJ3*01
B06_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV8-61*01 IGLJ3*01
B07_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*02
B09_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
B10_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV3-1*01 IGLJ3*01
B11_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-23*03 IGLJ3*02
B12_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV3-21*02 IGLJ3*02
C02_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*02
C06_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ4*01
C07_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-40*01 IGLJ1*01
C08_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV3-1*01 IGLJ3*01
C09_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV1-44*01 IGLJ3*01
C10_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV2-11*01 IGLJ3*02
C11_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-40*01 IGLJ3*01
D01_4519__f IGHV1-18*01 IGHD3-10*01 IGHJ6*02 IGLV1-44*01 IGLJ1*01
D02_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-14*04 IGLJ3*01
D03_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ1*01
D04_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ1*01
D05_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV1-44*01 IGLJ3*02
D06_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGLV1-40*01 IGLJ3*01
D07_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*02
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D09_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-47*02 IGLJ3*01
D11_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
D12_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV6-57*01 IGLJ3*01
E01_4519__f IGHV3-21*01 IGHD5-24*01 IGHJ3*02 IGLV3-1*01 IGLJ3*02
E02_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-47*01 IGLJ3*01
E03_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ3*01
E04_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ3*01
E05_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ5*02
E06_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-23*03 IGLJ3*02
E07_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3D-15*01 IGKJ5*01
E08_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 no family 
assigned: 
humIGLV114
IGLJ3*02
B08_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
C01_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-20*01 IGKJ5*01
C04_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ4*01
C05_4519__f IGHV4-39*01 IGHD6-6*01 IGHJ6*02 IGKV3-15*01 IGKJ5*01
D08_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV2-14*04 IGLJ3*01
D10_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-47*01 IGLJ3*02
C12_4519__f IGHV3-21*01 IGHD6-6*01inv IGHJ3*02 IGLV1-44*01 IGLJ3*01
101
 Supplemental Information
102
Figure 25: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero
cells are given as green dotted line. The threshold for neutralization is given as red dotted
line (50 % of untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open
symbol  and dotted  line)  are  considered as  negative  control,  ewe192-B5 (green,  open
symbol and dotted line) as positive control. All shown scFv-Fc antibodies were further
analyzed.  Mitochondrial  activity  was  measured  with  an  MTT assay  after  6  days  at
OD570nm.
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Figure 26: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
given as green dotted line. The threshold for neutralization is given as red dotted line (50 % of
untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open symbol and dotted line)
are considered as negative control, ewe192-B5 (green, open symbol and dotted line) as positive
control.  All  shown  scFv-Fc  antibodies  were  further  analyzed.  Mitochondrial  activity  was
measured with an MTT assay after 6 days at OD570nm.
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Figure 27: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
given as green dottet line. The threshold for neutralization is given as red dotted line (50 % of
untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open symbol and dotted line)
are considered as negative control, ewe192-B5 (green, open symbol and dotted line) as positive
control. Samples with gray or colored symbols were further analyzed, samples with black symbols
not. Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
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Figure 28: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
given as green dottet line. The threshold for neutralization is given as red dotted line (50 % of
untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open symbol and dotted line)
are considered as negative control, ewe192-B5 (green, open symbol and dotted line) as positive
control. Samples with gray or colored symbols were further analyzed, samples with black symbols
not. Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
 Supplemental Information
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Figure 29: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
given as green dottet line. The threshold for neutralization is given as red dotted line (50 % of
untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open symbol and dotted line)
are considered as negative control, ewe192-B5 (green, open symbol and dotted line) as positive
control. Samples with gray or colored symbols were further analyzed, samples with black symbols
not. Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
 Supplemental Information
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Figure 30: Neutralization assay of scFv-Fc in supernatant for screening. Untreated Vero cells are
given as green dottet line. The threshold for neutralization is given as red dotted line (50  % of
untreated Vero cells). The antibodies TM43-E10 and JöJ58B9 (red, open symbol and dotted line)
are considered as negative control, ewe192-B5 (green, open symbol and dotted line) as positive
control.  Samples  with  gray  or  colored  symbols  were  further  analyzed,  samples  with  black
symbols not. Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
 Supplemental Information
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Figure  31: SDS-PAGE followed by Coomassie staining
of  purified domains  and fragments  of  diphtheria  toxin
produced in BLR(DE3).
Figure  32:  Western Blot  after  SDS-PAGE for  domain mapping of  scFv-Fc antibodies
derived  from panning with  antigen  in  solution.  All  scFv-Fc  antibodies  are  tested  on
fragments and domains of diphtheria toxin: A-fragment (A), B-fragment (B), R-domain
(C) and T-domain (D). 
A B
C D
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Figure  33:  Western Blot  after  SDS-PAGE for  domain mapping of  scFv-Fc antibodies
derived  from panning with  antigen  in  solution.  All  scFv-Fc  antibodies  are  tested  on
fragments and domains of diphtheria toxin: A-fragment (A and B) and R-domain (C &
D), B-fragment (E) and T-domain (F). 
A B
C D
E F
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Figure  34: Western Blot after SDS-PAGE and immunostain for domain mapping of scFv-Fc
antibodies derived from panning with immobilized antigen. All scFv-Fc antibodies are tested on
the two fragments of diphtheria toxin: A-fragment (A and B) and B-fragment (C & D). The
antibodies with positive reaction against B-fragment are further tested on the R-domain (E) and
T-domain (F).
A B
C D
E F
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Figure 35: Cell-based combination, neutralization assay of IgG antibodies. Untreated Vero
cells are given as green dotted line. The threshold for neutralization is given as red dotted
line (50% of untreated Vero cells). Single antibodies are given in a single color (full symbol,
solid line), combinations of antibodies are given in the colors the domain is binding against
(red = C-doamin, green = R-domain and blue = T-domain; filling of symbol and color of line
variates). Mitochondrial activity was measured with an MTT assay after 6 days at OD570nm.
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Figure  36: Specificity Immuno Blot. Western blot after SDS-PAGE of EXPI293F cell lysate and
stained with DT neutralizing IgG antibodies. Detection with goat α-human Fc secondary antibody
conjugated with AP and colored with AP substrate + NBT/BCIP.
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